Rank	NCT Number	Title	Recruitment	Study Results	Conditions	Interventions	Sponsor/Collaborators	Gender	Age Groups	Phases	Enrollment	Funded Bys	Study Types	Study Designs	Other IDs	First Received	Start Date	Completion Date	Last Updated	Last Verified	Results First Received	Acronym	Primary Completion Date	Outcome Measures	URL
1	NCT02153515	Treating Dry Eyes and Corneal Ulcers With Fingerprick Autologous Blood	Enrolling by invitation	No Results Available	Dry Eyes|Sjogren's Disease With Dry Eyes|Persistent Corneal Epithelial Defects|Chronic Corneal Ulcers	Other: Your own ( autologous) finger prick of blood produced with a diabetic lancet	Bedford Hospital NHS Trust|Moorfields Eye Hospital NHS Foundation Trust|The Mater Infirmary Hospital Belfast, UK.|Milton Keynes General NHS Trust|Heart of England NHS Trust|University Hospitals Bristol NHS Foundation Trust|Birmingham Midland Eye Centre, UK	Both	Child|Adult|Senior	Phase 3	60	Other	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	426/2014/340	May 2, 2014	April 2014	August 2016	May 30, 2014	May 2014	No Study Results Posted	FAB	February 2016	Corneal ulcers / epithelial defects: Ulcers to heal within 4 weeks. Dry eyes: To improve signs (corneal and conjunctival staining, Schirmer's test, tear break up time ) or symptoms ( ocular comfort index questionnaire)	https://ClinicalTrials.gov/show/NCT02153515
2	NCT02004067	Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease	Active, not recruiting	No Results Available	Primary Sjogren Syndrome|Secondary Sjogren Syndrome|Aqueous Deficient Dry Eye Disease|Evaporative Dry Eye Disease	Drug: Restasis|Drug: Refresh Endura	Federal University of São Paulo|Allergan	Both	Adult	Phase 4	100	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	CAAE: 17821013.0.0000.5505	December 3, 2013	January 2013	February 2016	August 10, 2015	August 2015	No Study Results Posted	null	November 2015	Ocular surface inflammation	https://ClinicalTrials.gov/show/NCT02004067
3	NCT02188160	Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease	Completed	No Results Available	Dry Eye Syndromes|Keratoconjunctivitis Sicca	Drug: KPI-121	Kala Pharmaceuticals, Inc.	Both	Adult|Senior	Phase 2	150	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	KPI-121-C-002	July 9, 2014	June 2014	March 2015	March 30, 2015	March 2015	No Study Results Posted	Kauai	January 2015	Bulbar Conjunctival Hyperemia|Ocular Discomfort	https://ClinicalTrials.gov/show/NCT02188160
4	NCT02210793	Dry Eye Evaluation After Transepithelial PRK	Completed	No Results Available	Dry Eye	Procedure: transepithelial PRK|Procedure: LASIK	AL-Nour Eye Hospital	Both	Adult		40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Screening|Masking: Open Label	ANH-1|ANH-TPRK1	August 2, 2014	April 2012	March 2013	August 5, 2014	August 2014	No Study Results Posted	null	March 2013	qualitative assessment of dry eye syndrome|quantitative of dry eye after surgery|haze	https://ClinicalTrials.gov/show/NCT02210793
5	NCT01988597	Dry Eye Symptoms and Quality of Life	Completed	No Results Available	Dry Eyes	Other: Dry eyes	Singapore National Eye Centre	Both	Adult|Senior		200	Other	Observational	Observational Model: Case Control|Time Perspective: Cross-Sectional	R1047/62/2013|2013/595/A	November 13, 2013	September 2013	April 2014	June 9, 2014	June 2014	No Study Results Posted	null	April 2014	• Difference in SPEED Questionnaire and SANDE Questionnaire that affects patient health related quality of life (HRQOL)|• Difference in both (SPEED and SANDE) questionnaires and utility values that affects patient health related quality of life (HRQOL)|Production of Tear flow|Tear break up time (TBUT)|Corneal flourescein staining	https://ClinicalTrials.gov/show/NCT01988597
6	NCT02051023	Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)	Completed	No Results Available	Dry Eye	Drug: FML 0.1% eyedrops|Drug: Liquifilm artificial tears eyedrops	Instituto Universitario de Oftalmobiología Aplicada	Both	Adult|Senior	Phase 3	41	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	IOBA-CERLAB-003-2013	January 22, 2014	February 2014	December 2014	January 7, 2015	January 2015	No Study Results Posted	FML	December 2014	Fluorescein corneal staining|Symptom Assessment in Dry Eye (SANDE) I and II questionnaire|Tear inflammatory molecule levels|Best corrected visual acuity|Biomicroscopy findings at slit lamp examination|Adverse events during the trial|Other Efficacy Measures|Intraocular pressure (IOP) and fundus examination	https://ClinicalTrials.gov/show/NCT02051023
7	NCT01880463	Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)	Active, not recruiting	No Results Available	Dry Eye Disease	Drug: Omega-3 fatty acids (fish oil)|Dietary Supplement: Vitamin D3	Brigham and Women's Hospital|National Eye Institute (NEI)	Both	Adult|Senior		25875	Other|NIH	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	2012P001332|R01EY022663	June 15, 2013	July 2010	October 2017	May 29, 2014	May 2014	No Study Results Posted	null	October 2017	Dry Eye Disease	https://ClinicalTrials.gov/show/NCT01880463
8	NCT02306668	Ocular Surface Dry Eye Microbiome	Recruiting	No Results Available	Dry Eyes		University of Washington	Both	Adult|Senior		80	Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	46093-B	December 1, 2014	February 2014	December 2016	December 2, 2014	December 2014	No Study Results Posted	null	December 2016	Identification of bacteria or fungus from conjunctival swab	https://ClinicalTrials.gov/show/NCT02306668
9	NCT02218827	Topical Steroid Treatment For Dry Eye	Not yet recruiting	No Results Available	Dry Eye	Drug: Loteprednol Etabonate (FML)	Meir Medical Center	Both	Adult|Senior		30	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	dry eye01	August 14, 2014	September 2014	September 2015	August 14, 2014	August 2014	No Study Results Posted	null	September 2015	clinical improvement in dry eye measurements|symptomatic improvement	https://ClinicalTrials.gov/show/NCT02218827
10	NCT02116244	Civamide Nasal Solution for Dry Eye	Recruiting	No Results Available	Dry Eye	Drug: Civamide Nasal Spray	Winston Laboratories	Both	Adult|Senior	Phase 2	20	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	WL-1001-08-02	April 14, 2014	May 2014	October 2015	June 2, 2015	September 2014	No Study Results Posted	null	September 2015	Schirmer Test	https://ClinicalTrials.gov/show/NCT02116244
11	NCT02078661	Safety and Efficacy of PG101 for Dry Eye Syndrome	Completed	No Results Available	Dry Eye Syndrome	Drug: PG101	Rhodes Pharmaceuticals, L.P.|ORA, Inc.	Both	Adult|Senior	Phase 1|Phase 2	72	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	RP-PG-EF001|13-110-0002	December 20, 2013	December 2013	January 2014	March 3, 2014	March 2014	No Study Results Posted	PG101	January 2014	At least one dry eye ocular symptom|At least one dry eye ocular sign measure.	https://ClinicalTrials.gov/show/NCT02078661
12	NCT01918410	Effect of Contact Lens With Alginic Acid in Dry Eye Patients	Completed	No Results Available	Dry Eyes	Device: Contact Lens with alginic acid|Device: Contact Lens without alginic acid	Louis Tong|Singapore Eye Research Institute|SEED Company Pte Ltd|Singapore National Eye Centre	Both	Adult|Senior		30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)	SEED2013	August 6, 2013	February 2014	December 2014	May 18, 2015	June 2014	No Study Results Posted	null	December 2014	• Difference of Visual Analogue Scale (VAS) for the ocular discomfort between control and treatment group.|Tear lipid layer thickness measurements of LipiView|Schirmers I reading|Tear break up time (TBUT)|Corneal flourescein staining|Tear proteomic analysis	https://ClinicalTrials.gov/show/NCT01918410
13	NCT02193490	DNase Treatment for Dry Eyes	Recruiting	No Results Available	Dry Eye	Drug: DNase|Drug: Vehicle	University of Illinois at Chicago|Research to Prevent Blindness|Genentech, Inc.	Both	Adult|Senior	Phase 1|Phase 2	72	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	UIC-CNBL-1001	July 15, 2014	July 2014	December 2016	June 29, 2015	June 2015	No Study Results Posted	null	October 2016	Reduction in ocular surface staining as measured by Rose Bengal dye staining|The change in the Ocular Surface Disease Index score|Change in ocular surface redness score on slit-lamp examination|Change in tear secretion as measured by Schirmer I test|The proportion of eyes achieving complete ocular surface staining clearance after treatment|Visual acuity change|Change in number of corneal filaments (on slit-lamp examination)	https://ClinicalTrials.gov/show/NCT02193490
14	NCT01957670	Pilot Study to Clinical Evaluate Device Prototypes in Dry Eye Patients	Not yet recruiting	No Results Available	Dry Eye Syndrome	Device: Lacrima medical Prototypes	Lacrima Medical LTD	Both	Adult|Senior		100	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	LM001	September 30, 2013	February 2016	January 2018	September 1, 2015	September 2015	No Study Results Posted	null	December 2017	Lower Tear Meniscus Height using Optical Coherence Tomography|Visual Analog Scale score	https://ClinicalTrials.gov/show/NCT01957670
15	NCT01967147	Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects	Completed	No Results Available	Dry Eye	Drug: Propylene Glycol, 0.6% eye drops|Drug: Preservative-free 0.9% Saline solution	Alcon Research	Both	Adult|Senior		278	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	M-13-027	October 18, 2013	February 2014	January 2015	January 16, 2015	January 2015	No Study Results Posted	null	January 2015	Change from baseline in tear film break-up time (TFBUT) at Day 35|Change from baseline in Total Ocular Surface Staining (TOSS) score at Day 35|Change from baseline in ocular surface disease index (OSDI) score at Day 35|Change from baseline in Impact of Dry Eye on Everyday Life (IDEEL) Treatment Effectiveness score at Day 35|Change from baseline in IDEEL Treatment Inconvenience score at Day 35	https://ClinicalTrials.gov/show/NCT01967147
16	NCT02365519	LME636 in the Relief of Persistent Ocular Discomfort in Patients With Severe Dry Eye Disease	Active, not recruiting	No Results Available	Dry Eye	Biological: LME636 ophthalmic solution|Biological: LME636 Vehicle	Alcon Research	Both	Adult|Senior	Phase 2	380	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	LME636-2202	February 13, 2015	March 2015	October 2015	August 11, 2015	August 2015	No Study Results Posted	null	October 2015	Mean change from baseline in global ocular discomfort score|Best corrected visual acuity (BCVA)|Intraocular pressure (IOP)|Slit lamp parameters|Dilated fundus parameters|Percentage of patients with improvement in global ocular discomfort score >20|Frequency of concentrations below the lower limit of quantification (LLOQ)|Frequency of subjects with anti-LME636 antibodies	https://ClinicalTrials.gov/show/NCT02365519
17	NCT02522312	A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients	Not yet recruiting	No Results Available	Dry Eye Syndrome	Other: No Intervention	Hazleton Eye Specialists	Both	Adult|Senior		100	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	IIT-00864	July 29, 2015	August 2015	October 2015	August 10, 2015	August 2015	No Study Results Posted	null	October 2015	Improvement of Schirmer's Test score|Increased contact lens wear time	https://ClinicalTrials.gov/show/NCT02522312
18	NCT02376556	The Effect of Eyelid Surgery on Dry Eye - a Prospective Study	Not yet recruiting	No Results Available	Dry Eye Syndrome|Ptosis|Dermatochalasis		Sheba Medical Center	Both	Adult|Senior		60	Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	SHEBA-14-1496-GBS-CTIL	February 25, 2015	March 2015	null	June 14, 2015	June 2015	No Study Results Posted	null	March 2017	dry eye syndrome	https://ClinicalTrials.gov/show/NCT02376556
19	NCT01843894	A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye	Completed	No Results Available	Dry Eye	Biological: RU-101	R-Tech Ueno, Ltd.	Both	Adult|Senior	Phase 1|Phase 2	104	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	RU-101-C001	April 12, 2013	April 2013	July 2014	August 20, 2014	August 2014	No Study Results Posted	null	July 2014	Occular Adverse Events|Symptoms|Signs|Non-Occular Adverse Events	https://ClinicalTrials.gov/show/NCT01843894
20	NCT02403219	Paralysis of the Orbicularis Muscle of the Eye in the Treatment for Dry Eye	Completed	No Results Available	Dry Eye Syndromes	Drug: Botulinum toxin type A injection|Other: Saline solution injection	Instituto de Oftalmología Fundación Conde de Valenciana	Both	Adult|Senior	Phase 1	20	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	CEI-2013-/06/06	January 21, 2015	May 2013	January 2015	March 30, 2015	March 2015	No Study Results Posted	null	February 2014	Symptoms of dry eye (questionnaire)|Symptoms of conjunctivitis (questionnaire)|Quality of vision (graded perception of patient)|Ocular comfort level (graded perception of patient)|Moisturizing agent usage (patient will be asked how many times a day does he use the moisturizing agent and will be graded from 0 to 5 according to the frequency)|Visual acuity (Snellen vision acuity)|Measurement of the tear film break up time (After fluorescein staining, the time required for dry spots to appear on the corneal surface after blinking)|Schirmer's test|Oxford grading scheme for corneal and conjunctival staining	https://ClinicalTrials.gov/show/NCT02403219
21	NCT01797822	Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca	Recruiting	No Results Available	Keratoconjunctivitis Sicca|Dry Eye Syndrome	Drug: dexamethasone, artificial tears	Baylor College of Medicine	Both	Adult|Senior		30	Other	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	H-31756	February 21, 2013	February 2013	null	July 20, 2015	July 2015	No Study Results Posted	null	December 2015	Changes in ocular surface measured by routine opthalmic dyes	https://ClinicalTrials.gov/show/NCT01797822
22	NCT02101281	Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye	Completed	No Results Available	Dry Eye Syndrome.	Biological: Human nerve growth factor 20 µg/mL|Biological: Human nerve growth factor 4 µg/mL or 60 µg/mL	Dompé Farmaceutici S.p.A|Cross Research S.A.	Both	Adult|Senior	Phase 2	40	Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	NGF0213|2013-004271-12	March 20, 2014	March 2014	January 2015	July 27, 2015	July 2015	No Study Results Posted	null	January 2015	Symptom Assessment in Dry Eye (SANDE)|Ocular surface vital staining|Schirmer test type I|Treatment-emergent adverse events (TEAEs),|Visual analogue scale (VAS)|Slit lamp examination|Schirmer test type II (with anaesthesia)|Tear Film Break-Up Time (TFBUT)|Corneal fluorescein staining|Corneal sensitivity (Cochet-Bonnet aesthesiometry)|Intraocular Pressure (IOP)|Ocular Surface Disease Index (OSDI)|Visual acuity|Fundus ophthalmoscopy|Tear Film osmolarity|Conjunctival impression cytology for goblet cells' count Tear Film osmolarity|Frequency of artificial tears use	https://ClinicalTrials.gov/show/NCT02101281
23	NCT02242032	Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease	Completed	No Results Available	Dry Eye Disease	Drug: P-321 Ophthalmic Solution|Drug: P-321 Ophthalmic Solution placebo	Parion Sciences	Both	Adult|Senior	Phase 1	53	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	P-321-101	August 28, 2014	July 2014	March 2015	May 1, 2015	May 2015	No Study Results Posted	null	March 2015	Number of subjects with adverse events|Changes from baseline in 14 days in visual acuity.|Change from baseline at 28 days in visual acuity for Cohort 4 only.|Changes from baseline at 14 days in corneal staining.|Changes from baseline at 28 days in corneal staining for cohort 4 only.|Changes from baseline at 14 days in conjunctival staining.|Changes from baseline at 28 days in conjunctival staining for Cohort 4 only.|Changes from baseline at 14 days in intraocular pressure.|Changes from baseline at 28 days in intraocular pressure. for Cohort 4 only.|Changes from baseline at 14 days in ophthalmoscopy.|Changes from baseline at 28 days in ophthalmoscopy for Cohort 4 only.|Measure plasma P-321 concentrations|Measure urine concentrations of P-321|Measure tear concentrations of P-321|Measure plasma P-321 concentrations in Cohort 4|Measure urine concentrations of P-321 in Cohort 4|Measure tear concentrations of P-321 in Cohort 4	https://ClinicalTrials.gov/show/NCT02242032
24	NCT01804361	Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes	Completed	No Results Available	Dry Eye Syndromes	Drug: Haporine-S|Drug: Restasis (cyclosporine 0.05%)	DH Bio Co., Ltd.|BTO Pharm. Co., Ltd.	Both	Adult|Senior	Phase 3	90	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Investigator, Outcomes Assessor)	UMT-2012-DH-HS-01|1360-8040-3073-4190	February 27, 2013	March 2013	February 2014	July 20, 2015	July 2015	No Study Results Posted	null	February 2014	Corneal staining|Ocular Surface Disease Index(OSID)|Tear Breakup Time(TBUT)|Schirmer score|Drug compliance|DEWS(Dry Eye WorkShop) level	https://ClinicalTrials.gov/show/NCT01804361
25	NCT02120079	The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease	Recruiting	No Results Available	Dry Eye Disease	Drug: Lotemax|Drug: Artificial Tears	Massachusetts Eye and Ear Infirmary|GlaxoSmithKline	Both	Adult|Senior	Phase 4	50	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	13-150H	February 12, 2014	February 2014	null	December 7, 2014	April 2014	No Study Results Posted	null	July 2015	In Vivo Confocal Microscopy (IVCM): Superficial corneal epithelial cells: Density, size, and hypereflectivity|In Vivo Confocal Microscopy: Corneal subbasal immune dendritiform cells: Density, size, and cell field|In Vivo Confocal Microscopy: Corneal subbasal nerves: Number and length of the main nerves and the branches|Ocular Signs: Corneal epitheliopathy|Ocular Signs: Conjunctival epitheliopathy|Ocular Signs: Tear Break Up Time (TBUT)|Ocular Signs: Schirmer's Test with Anesthesia|Ocular Signs: Intraocular pressure (IOP) by measure of applanation tonometry|Ocular Symptoms: Ocular Surface Disease Index (OSDI) questionnaire|Ocular Symptoms: • Symptom Assessment iN Dry Eye (SANDE) questionnaire	https://ClinicalTrials.gov/show/NCT02120079
26	NCT02042820	Ocular Surface Immune Response in Dry Eye Disease: Analysis of Conjunctival and Peripheral Corneal Immune Cell Alterations by In Vivo Confocal Microscopy and Clinical Correlation	Recruiting	No Results Available	Dry Eye Disease	Other: In vivo confocal microscopy (IVCM)	Massachusetts Eye and Ear Infirmary	Both	Adult|Senior		75	Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	13-149H	January 17, 2014	January 2014	null	December 24, 2014	December 2014	No Study Results Posted	null	January 2016	Peripheral Corneal Immune cell Status by IVCM|Bulbar conjunctival immune cell Status by IVCM|Clinical Parameter: Ocular Surface Disease Index (OSDI)|Clinical Parameter: Schirmer's II test|Clinical Parameter: Conjunctival staining with lissamine green|Clinical Parameter: Corneal staining with fluorescein|Clinical Parameter: Tear Break Up Time (TBUT)|Clinical Parameter: Conjunctival redness	https://ClinicalTrials.gov/show/NCT02042820
27	NCT02313454	Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye	Completed	No Results Available	Dry Eye Syndromes	Device: Oculeve Intranasal Lacrimal Neurostimulator	Oculeve, Inc.|ORA, Inc.	Both	Adult|Senior		19	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	OCUN-007	December 8, 2014	December 2014	April 2015	April 27, 2015	April 2015	No Study Results Posted	null	April 2015	Dry eye symptom assessment|Application preference	https://ClinicalTrials.gov/show/NCT02313454
28	NCT02510235	Tolerability, Safety and Efficacy of Lubricin Eye Drops Versus Sodium Hyaluronate Eye Drops in Subjects With Moderate Dry Eye	Completed	No Results Available	Dry Eye Syndrome|Tear Film Insufficiency	Device: Lubricin|Device: Sodium Hyaluronate	Dompé Farmaceutici S.p.A	Both	Adult|Senior		56	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	LUB0114MD	July 27, 2015	March 2015	June 2015	July 28, 2015	July 2015	No Study Results Posted	null	May 2015	SANDE|Ocular Total Tolerability Score|Oxford score|Tear Osmolarity|Schirmer-I Test|Tear Film Break Up Time|Best corrected distance visual|Corneal fluorescein surface staining (Oxford score)|IOP|TEAE	https://ClinicalTrials.gov/show/NCT02510235
29	NCT02507934	Tolerability, Safety and Efficacy of Lubricin (150 µg/ml) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops in Patients With Moderate Dry Eye (DE)	Recruiting	No Results Available	Dry Eye Syndrome	Device: Lubricin|Device: Sodium Hyaluronate	Dompé Farmaceutici S.p.A	Both	Adult|Senior		40	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	LUB0115MD	July 23, 2015	June 2015	October 2015	July 23, 2015	June 2015	No Study Results Posted	null	September 2015	PTAE (pre-treatment adverse events)|Foreign body sensation (VAS for Local Ocular Tolerability)|Burning/Stinging (VAS for Local Ocular Tolerability)|Itching (VAS for Local Ocular Tolerability)|Pain (VAS for Local Ocular Tolerability)|Sticky feeling (VAS for Local Ocular Tolerability)|Blurred vision (VAS for Local Ocular Tolerability)|Photophobia (VAS for Local Ocular Tolerability)|TEAE (treatment-emergent adverse events)|Corneal fluorescein surface staining (Oxford score)|TFBUT (Tear Film Break Up Time)|SANDE (Symptom Assessment in Dry Eye)|Schirmer Test I (without anaesthesia)|Best corrected distance visual acuity (ETDRS Score)	https://ClinicalTrials.gov/show/NCT02507934
30	NCT02011776	A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome	Completed	No Results Available	Dry Eye Syndromes|Sjögren Syndrome		Santen Pharmaceutical(China) Co.,LTD	Both	Adult|Senior		35	Industry	Observational	Observational Model: Case Control|Time Perspective: Prospective	FML-001	December 10, 2013	March 2013	November 2013	July 7, 2014	July 2014	No Study Results Posted	null	August 2013	tear—film breakup time|Schirmer test I without anesthesia|corneal fluorescein staining	https://ClinicalTrials.gov/show/NCT02011776
31	NCT02229955	Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease	Completed	No Results Available	Dry Eye Syndromes	Drug: Cyclosporine ophthalmic solution	Hanlim Pharm. Co., Ltd.	Both	Adult|Senior	Phase 3	86	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	HL_TSPR_302	August 29, 2014	December 2013	July 2014	September 2, 2014	August 2014	No Study Results Posted	HL_TSPR_302	April 2014	Corneal staining test|Ocular surface disease index (OSDI)|Tear break up time (TBUT)|Non-anesthetic Schirmer test|Conjunctival staining	https://ClinicalTrials.gov/show/NCT02229955
32	NCT02147509	Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome	Completed	No Results Available	Sjögren's Syndrome Patients With Severe Dry Eye	Drug: 0.02% Fm, SH|Drug: 0.02% Fm, SH, 0.05% CsA|Other: 0.02% Fm, SH, tBCL|Drug: 0.02% Fm, SH, AS	Jinyang Li|Wenzhou Medical University	Both	Adult|Senior		64	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	BCL-018-SS	May 13, 2014	March 2013	April 2014	July 20, 2014	July 2014	No Study Results Posted	BCL	April 2014	C Corneal fluorescein staining|Visual acuity|Tear film breakup time|Schirmer I test|quality of the life|Symptom of the dryness	https://ClinicalTrials.gov/show/NCT02147509
33	NCT02420834	Dry Eye Treatment With Artificial Tears	Recruiting	No Results Available	Dry Eye	Other: Hypromellose 0.15%|Other: Hypromellose 0.4%|Other: Carboxymethylcellulose|Other: Liposomal Spray	Aston University	Both	Adult|Senior	Phase 4	50	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	DOptomEssa	April 10, 2015	April 2015	August 2015	April 15, 2015	April 2015	No Study Results Posted	null	August 2015	Symptoms|Non-invasive break-up time|Tear meniscus height|lid parallel conjunctival folds|Ocular Surface Staining|Phenol Red Test	https://ClinicalTrials.gov/show/NCT02420834
34	NCT02128763	Dry Eye Assessment and Management Study	Recruiting	No Results Available	Dry Eye	Drug: Omega-3 supplements|Drug: Placebo	University of Pennsylvania|National Eye Institute (NEI)	Both	Adult|Senior	Phase 3	600	Other|NIH	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	UPenn IRB Protocol 816490|U10EY022879|U10EY022881	April 28, 2014	November 2014	April 2017	October 8, 2015	October 2015	No Study Results Posted	DREAM	April 2016	Mean of change from baseline in OSDI score at 6 and 12 months (Primary Trial). Mean of change from 12 months in OSDI score at 18 and 24 months (Extension Study)|Compliance with the study treatment protocol as measured by changes in blood levels of fatty acids and pill counts|Greater than or equal to 10 point change in OSDI|Change in conjunctival staining score|Change in corneal fluorescein staining score|Change in tear film break up time|Change in Schirmer's test mm|Change in use of artificial tears and other treatments for dry eye disease|Change in SF-36 score|Change in the Brief Ocular Discomfort Index score|Change in healthcare utilization costs|Difference in cost effectiveness between groups on active and placebo supplements	https://ClinicalTrials.gov/show/NCT02128763
35	NCT02417116	Tear Osmolarity Clinical Utility in Dry Eye Disease	Recruiting	No Results Available	Dry Eye	Other: Tear supplement|Other: Tear supplement 2|Dietary Supplement: Omega 3 nutrition supplement|Device: Eye bag|Other: Saline	Aston University|TearLab Corporation	Both	Adult|Senior	Phase 4	120	Other|Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	TP00128	April 10, 2015	June 2015	December 2015	June 30, 2015	June 2015	No Study Results Posted	null	December 2015	Osmolarity change|Tear break-up time change|Corneal staining change|Meibomian gland change|Tear Meniscus Height|SPEED Questionnaire change	https://ClinicalTrials.gov/show/NCT02417116
36	NCT01959854	Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye	Completed	No Results Available	Dry Eye	Device: carboxymethylcellulose|Device: xanthan gum	SIFI SpA	Both	Adult|Senior		30	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	XNTME2013	October 7, 2013	September 2013	October 2014	October 15, 2014	October 2014	No Study Results Posted	null	October 2014	Ocular surface disease index (OSDI)|Visual analogue rating scale (VARS)|Fluorescein staining	https://ClinicalTrials.gov/show/NCT01959854
37	NCT01850979	Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops	Completed	No Results Available	Sjogren Syndrome|Dry Eye Syndrome	Drug: Tacrolimus|Drug: Olive Oil	University of Sao Paulo General Hospital	Both	Adult	Phase 4	24	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Investigator, Outcomes Assessor)	1307/09	May 1, 2013	February 2010	November 2011	May 9, 2013	May 2013	No Study Results Posted	null	November 2011	Evaluation of the quantity of lacrimal film|Evaluation of quality of lacrimal film	https://ClinicalTrials.gov/show/NCT01850979
38	NCT02257957	Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye	Not yet recruiting	No Results Available	Dry Eye|Sjogren Syndrome	Drug: PRP injection|Drug: Standard care Hyaluronic acid eye drops	Universidad Nacional de Colombia	Both	Adult|Senior	Phase 3	30	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	plasmadry10	September 24, 2014	November 2014	null	October 2, 2014	October 2014	No Study Results Posted	null	September 2015	Corneal Staining Change|Shirmer test Change|Ocular Surface Disease Index (OSDI ) Change|Treatment compliance	https://ClinicalTrials.gov/show/NCT02257957
39	NCT02511379	Clinical Evaluation of Systane® Balance in Dry Eye Subjects	Not yet recruiting	No Results Available	Dry Eye	Other: Propylene Glycol 0.6% eye drops	Alcon Research	Both	Adult		200	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	EXJ821-P001 (C-13-039)	July 28, 2015	October 2015	May 2016	August 25, 2015	August 2015	No Study Results Posted	null	May 2016	Change From Baseline in Corneal Staining Score at all study time points	https://ClinicalTrials.gov/show/NCT02511379
40	NCT02380248	Clinical Evaluation of Systane® Gel Drops in Dry Eye Subjects	Recruiting	No Results Available	Dry Eye	Other: Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops	Alcon Research	Both	Adult		200	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	EXI639-P001 (C-13-040)	March 2, 2015	May 2015	January 2016	September 25, 2015	September 2015	No Study Results Posted	null	January 2016	Change from baseline in corneal staining at all study time points	https://ClinicalTrials.gov/show/NCT02380248
41	NCT02405039	Study of EBI-005 in Dry Eye Disease (DED)	Active, not recruiting	No Results Available	Dry Eye	Drug: EBI-005|Drug: Placebo	Eleven Biotherapeutics	Both	Adult|Senior	Phase 3	188	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)	EBI-005-4	January 6, 2015	April 2015	July 2016	June 2, 2015	June 2015	No Study Results Posted	EBI-005	June 2016	Safety of EBI-005 (vital signs)|tolerability of EBI-005 (adverse events)|Immunogenicity of EBI-005 (assessment of antibody development (immunogenicity) over time)|Safety of EBI-005 (laboratory changes over time)|Biological effect of EBI-005 (Changes over time in the OSDI)|Biological effect of EBI-005 (Total corneal fluorescein staining)	https://ClinicalTrials.gov/show/NCT02405039
42	NCT02252744	Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis	Completed	No Results Available	Dry Eye Syndromes|Rheumatoid Arthritis		Western University of Health Sciences|Allergan	Both	Adult|Senior		286	Other|Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	WesternU-12irb027	September 18, 2014	November 2012	December 2014	May 28, 2015	May 2015	No Study Results Posted	null	June 2014	Percentage of patients diagnosed with rheumatoid arthritis with dry eye disease|Relationship between rheumatoid arthritis severity and dry eye disease severity|Relationship between rheumatoid arthritis severity and dry eye disease symptoms	https://ClinicalTrials.gov/show/NCT02252744
43	NCT02102464	Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers	Active, not recruiting	No Results Available	Meibomian Gland Dysfunction|Dry Eye	Device: LipiFlow treatment	TearScience, Inc.	Both	Adult|Senior		55	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label	LF006	March 30, 2014	April 2014	September 2015	February 4, 2015	February 2015	No Study Results Posted	null	August 2015	Mean change in Meibomian Gland Score from Baseline|Mean change in Dry Eye Questionnaire Score from Baseline	https://ClinicalTrials.gov/show/NCT02102464
44	NCT02219204	Randomised Research Comparing Acupuncture, Herbal Treatment and Artificial Tear Eye Drops in Dry Eye	Recruiting	No Results Available	Dry Eye	Procedure: Acupuncture|Other: Herbal treatment	Singapore National Eye Centre	Both	Adult|Senior		150	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)	R1142/44/2014|2014/398/A	August 14, 2014	March 2015	January 2016	May 18, 2015	June 2014	No Study Results Posted	null	January 2016	Change in discomfort SANDE score|Change in Tear Evaporimetry|Change in SPEED score|Change in TCM score (Lung-Kidney Yin deficiency)|Change in Non Invasive Break Up Time|Change in Schirmers I|Change in Corneal fluorescein staining|Change in Tear osmolarity|Change in Tear meniscus height|Change in Tear protein/ cytokine levels	https://ClinicalTrials.gov/show/NCT02219204
45	NCT01791426	A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye	Withdrawn	No Results Available	Dry Eye	Device: Artelac Rebalance|Device: Vismed	Bausch & Lomb Incorporated	Both	Adult|Senior		0	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)	810	February 4, 2013	May 2013	October 2013	October 10, 2013	October 2013	No Study Results Posted	null	October 2013	Combined Ocular Surface Staining Score|Corneal Fluorescein Staining Score|Nasal Conjunctival Lissamine Green Staining|Temporal Conjunctival Lissamine Green Staining|Tear Film Break-up Time|Study Drop Sensation	https://ClinicalTrials.gov/show/NCT01791426
46	NCT02235259	Efficacy and Safety of XG-104 for the Treatment of Dry Eye	Completed	No Results Available	Dry Eye	Drug: XG-104|Drug: Placebo	Xigen SA	Both	Adult|Senior	Phase 2	260	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	SDD-1004-059	September 5, 2014	September 2014	February 2015	February 19, 2015	February 2015	No Study Results Posted	null	February 2015	Corneal Fluorescein Staining: in the inferior region change from Pre-CAESM to Post- CAESM, as measured by the Ora CalibraTM Scale|Worst Dry Eye Symptom|Fluorescein Staining using Ora Calibra™ Scale and NEI Scale (all régions) Pre- and Post-CAESM|Lissamine Green Staining using Ora Calibra™ Scale and NEI Scale (all regions) (Pre- and Post-CAESM and change from Pre- to Post-CAESM|Tear Film Break-up Time (Pre- and Post-CAESM)|Conjunctival Redness using Ora Calibra™ Scale (Pre- and Post-CAESM)|Lid Margin Redness using Ora Calibra scale (Pre- and Post-CAESM)|Tear Osmolarity (Post-CAESM)|Blink Rate (Pre-CAESM ) using Ora Calibra™ Methodology|Ocular Protection Index (OPI 2.0) (Pre-CAESM ) using Ora Calibra™ Methodology|Unanesthetized Schirmer's Test (Pre-CAESM)|Drop Comfort and Symptom Assessment using Ora Calibra™ Scales|Ocular Surface Disease Index (OSDI) (Pre-CAESM)|Ocular Discomfort using Ora Calibra™ Scale (Pre and Post-CAESM)|Ocular Discomfort using Ora Calibra™ Discomfort and 4-Symptom Questionnaire (Pre and Post-CAESM)|Ocular Discomfort using Ora Calibra™ Scale (during CAESM exposure)|Daily diary	https://ClinicalTrials.gov/show/NCT02235259
47	NCT02160327	The Role of Cytokines and Mast Cell in the Pathogenesis of SLK, Conjunctivochalasis, and Dry Eye	Active, not recruiting	No Results Available	Superior Limbic Keratoconjunctivitis|Conjunctivochalasis|Dry Eye		National Taiwan University Hospital	Both	Adult|Senior		105	Other	Observational	Time Perspective: Prospective	201312127RINB	May 27, 2014	March 2014	December 2017	June 23, 2014	June 2014	No Study Results Posted	null	December 2017	Tear cytokines change measured by ELISA	https://ClinicalTrials.gov/show/NCT02160327
48	NCT02468700	Feasibility Study Evaluating Safety and Efficacy of OTX-DP (Sustained Release Dexamethasone, 0.4mg) for Treatment of Dry Eye	Active, not recruiting	No Results Available	Dry Eye	Drug: Sustained release dexamethasone, 0.4mg|Device: Placebo punctum plug, no drug	Ocular Therapeutix, Inc.	Both	Adult|Senior	Phase 2	43	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	OTX-14-006	June 4, 2015	December 2014	December 2015	June 8, 2015	June 2015	No Study Results Posted	null	December 2015	Corneal Fluorescein Staining and Conjunctival Lissamine Green Staining using the NEI Scale|SPEED Dry Eye Questionnaire|Tear Film Break Up Time (TBUT)|Presence of the punctum plug at all study visit time points through Day 30|Pain on the VAS scale	https://ClinicalTrials.gov/show/NCT02468700
49	NCT02369861	Study of ACCS Eye Drops in Treating Dry Eye	Recruiting	No Results Available	Dry Eye Syndrome	Drug: ACCS|Drug: Refresh Lubricant Eye Drops	David L Steed MD|U.S. Navy Bureau of Medicine|Stemnion, Inc.	Both	Adult|Senior	Phase 1	30	Industry|Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	ST-05-14	January 14, 2015	March 2015	December 2015	March 25, 2015	February 2015	No Study Results Posted	null	October 2015	Corneal staining with fluorescein|Lissamine staining|Endothelial cell count|Intraocular pressure|Tear volume|Assessment of structure and function of the eye|Assessment of Ocular Surface Disease Index (OSDI)	https://ClinicalTrials.gov/show/NCT02369861
50	NCT02446015	Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye	Recruiting	No Results Available	Dry Eye Syndrome	Drug: SYSTANE® ULTRA Lubricant Eye Drops	Alcon Research	Both	Adult|Senior		110	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)	EXC120-P001	May 13, 2015	June 2015	May 2016	June 23, 2015	June 2015	No Study Results Posted	null	May 2016	Change from Baseline in Total Ocular Surface Staining (TOSS) score at Day 28|Change from Baseline in Impact of Dry Eye on Everyday Life Symptom-Bother (IDEEL SB) score at Day 28|Change from Baseline in Impact of Dry Eye on Everyday Life Treatment Satisfaction (IDEEL TS) scores (treatment effectiveness and treatment-related inconvenience) at Day 28	https://ClinicalTrials.gov/show/NCT02446015
51	NCT02260960	The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease	Completed	No Results Available	Dry Eye Disease	Dietary Supplement: Omega-3 (Triglyceride form)	Physician Recommended Nutriceuticals	Both	Adult|Senior	Phase 2|Phase 3	122	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	PRN 20142	October 6, 2014	March 2014	March 2015	June 5, 2015	June 2015	No Study Results Posted	null	March 2015	Tear Osmolarity	https://ClinicalTrials.gov/show/NCT02260960
52	NCT01917539	Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome	Withdrawn	No Results Available	Meibomian Gland Dysfunction|Dry Eye Syndrome	Device: Sham Treatment|Device: Pulsed Light Therapy	University of Miami	Both	Adult|Senior		0	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)	20120140	July 19, 2013	June 2013	May 2015	June 17, 2015	June 2015	No Study Results Posted	null	May 2015	Anatomical improvement of the meibomian glands and their secretions.	https://ClinicalTrials.gov/show/NCT01917539
53	NCT02492412	Efficacy and Safety of HE10 for Dry Eye Syndrome	Completed	No Results Available	Dry Eye Syndrome	Drug: HE 10|Drug: Restasis	Huons Co.,Ltd.	Both	Adult|Senior	Phase 3	101	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	Huons	June 25, 2015	May 2013	September 2014	July 5, 2015	July 2015	No Study Results Posted	null	July 2014	Corneal staining Test to assess eye dryness	https://ClinicalTrials.gov/show/NCT02492412
54	NCT02023268	Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome	Recruiting	No Results Available	Dry Eye Syndrome	Device: T2762|Device: Vismed®	Laboratoires Thea	Both	Adult|Senior	Phase 3	76	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)	LT2762-PIII-08/13|2013-A01292-43	December 23, 2013	December 2013	null	March 13, 2014	March 2014	No Study Results Posted	null	December 2014	Global ocular staining	https://ClinicalTrials.gov/show/NCT02023268
55	NCT02014922	A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN)	Completed	No Results Available	Dry Eye Syndromes	Drug: TheraTears® Lubricant Eye Drop|Drug: TheraTears® preservative-free single-use containers|Dietary Supplement: TheraTears® Nutrition|Other: TheraTears® TheraLid® Eyelid Cleanser	University of Waterloo|Advanced Vision Research	Both	Adult	Phase 4	33	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)	P/439/13/AVR	December 12, 2013	December 2013	November 2014	March 9, 2015	March 2015	No Study Results Posted	DUNLIN	November 2014	Change over time of OSDI score|Change over time of Visual analogue scores|Change over time of Tear osmolarity|Change over time of Tear film breakup time|Change over time of Corneal staining|Change over time of Lid wiper epitheliopathy|Change over time of Meibomian gland expressibility|Change over time of Meibum quality|Change over time of Tear film lipid layer thickness|Change over time of Tear meniscus height|Change over time of Schirmer's I scores	https://ClinicalTrials.gov/show/NCT02014922
56	NCT01864330	Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome	Completed	No Results Available	Dry Eye Syndrome	Device: Thealoz Duo®|Device: Hyabak®|Device: Hydrabak®	Medical University of Vienna	Both	Adult|Senior	Phase 4	60	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	OPHT-28102012	May 3, 2013	May 2013	September 2013	November 26, 2013	November 2013	No Study Results Posted	null	August 2013	Tear film thickness|Tear Break Up Time|Subjective evaluation of ocular comfort|Schirmer I test|Visual Acuity|Intraocular Pressure	https://ClinicalTrials.gov/show/NCT01864330
57	NCT02326090	Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye	Completed	No Results Available	Dry Eye Syndrome	Drug: cis-UCA ophthalmic solution 1.0%|Drug: cis-UCA ophthalmic solution 2.5%|Drug: Placebo ophthalmic solution	Herantis Pharma Plc.|ORA, Inc.	Both	Adult|Senior	Phase 2	161	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	CL12002 / 14-110-0005	December 22, 2014	December 2014	April 2015	September 7, 2015	September 2015	No Study Results Posted	null	April 2015	Corneal Fluorescein Staining|Symptom Score	https://ClinicalTrials.gov/show/NCT02326090
58	NCT02533154	Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients	Not yet recruiting	No Results Available	Dry Eye Syndromes	Drug: Prosicca|Drug: Prosicca sine|Other: Bacterial culture	Medical University of Vienna	Both	Adult|Senior	Phase 4	40	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)	OPHT-280515	August 24, 2015	December 2015	null	August 24, 2015	August 2015	No Study Results Posted	null	March 2017	Number of colony forming units (CFU) in bacterial culture of conjunctival swab|Tear Break Up Time (BUT)|Schirmer I test|OSDI© score|Instillation frequency	https://ClinicalTrials.gov/show/NCT02533154
59	NCT01826812	Functional Impairment of Reading Ability in Dry Eye Patients and Effects of Sustained Reading on the Ocular Surface	Recruiting	No Results Available	Dry Eye Syndromes	Other: 30 minutes sustained reading|Other: Dry eye exam	Johns Hopkins University|Allergan	Both	Adult|Senior		200	Other|Industry	Observational	Observational Model: Case Control|Time Perspective: Prospective	NA_00082755	April 4, 2013	April 2013	June 2016	March 31, 2015	March 2015	No Study Results Posted	null	April 2016	Reading Speed|Ocular Surface Score|Tear Osmolarity|Visual Acuity|Cytokines	https://ClinicalTrials.gov/show/NCT01826812
60	NCT01998802	Phase 3 Study of EBI-005 in Dry Eye Disease	Completed	No Results Available	Dry Eye Disease (DED)	Drug: Active Comparator EBI-005|Drug: Placebo Comparator	Eleven Biotherapeutics	Both	Adult|Senior	Phase 3	670	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)	EBI-005-3	November 25, 2013	January 2014	April 2015	June 10, 2015	June 2015	No Study Results Posted	EBI-005	March 2015	NEI score for Total Corneal Fluorescein Staining (TCFS)|The key secondary endpoint is total OSDI score	https://ClinicalTrials.gov/show/NCT01998802
61	NCT02205840	A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.	Completed	No Results Available	Dry Eye Syndromes	Drug: SI-614|Drug: Vehicle	Seikagaku Corporation	Both	Adult|Senior	Phase 2|Phase 3	240	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	614/1131	July 30, 2014	July 2014	null	January 19, 2015	January 2015	No Study Results Posted	null	November 2014	Corneal staining score|Symptom score	https://ClinicalTrials.gov/show/NCT02205840
62	NCT02106377	Using in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Steroid Treatment in Dry Eye Disease	Recruiting	No Results Available	Dry Eye Syndrome	Drug: loteprednol etabonate (Lotemax)|Drug: Soothe Tired Eyes Lubricant Eye Drop	Massachusetts Eye and Ear Infirmary	Both	Adult|Senior		50	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	537897	April 3, 2014	February 2014	October 2015	April 7, 2014	April 2014	No Study Results Posted	null	July 2015	To evaluate the efficacy of Lotemax as compared to Soothe Tired Eyes Lubricant Eye Drop , using clinical and in vivo confocal microscopic findings.	https://ClinicalTrials.gov/show/NCT02106377
63	NCT02284516	A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye	Active, not recruiting	No Results Available	Dry Eye Disease	Drug: Lifitegrast|Drug: Placebo	Shire	Both	Adult|Senior	Phase 3	700	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	SHP606-304	October 30, 2014	November 2014	October 2015	October 6, 2015	July 2015	No Study Results Posted	OPUS-3	October 2015	Patient-Reported Eye Dryness Score|Patient-Reported Eye Discomfort Score|Patient-Reported Symptom Scores|Adverse Events	https://ClinicalTrials.gov/show/NCT02284516
64	NCT02461719	Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes	Completed	No Results Available	Dry Eye Syndromes	Drug: CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|Drug: Restasis	Taejoon Pharm Co., Ltd.	Both	Adult|Senior	Phase 3	158	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)	TJCS_P3	June 1, 2015	January 2014	October 2014	June 2, 2015	May 2015	No Study Results Posted	null	September 2014	Corneal staining test|Conjunctival staining|Corneal and Conjunctival staining sum Score|Ocular surface disease index (OSDI)|Tear break up time (TBUT)|Non-anesthetic Schirmer test|Frequency of concurrent drug use	https://ClinicalTrials.gov/show/NCT02461719
65	NCT02092207	Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome	Completed	No Results Available	Dry Eye Syndrome	Drug: KL7016 900mg|Drug: KL7016 600mg|Drug: Placebo	KT&G Life Sciences Corp	Both	Adult|Senior	Phase 2	147	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)	KL7016_201	March 17, 2014	October 2012	July 2014	August 8, 2014	August 2014	No Study Results Posted	null	June 2014	Change in corneal staining score|Change in schirmer test score|Change in OSDI(Ocular Surface Disease Index)|Change in TFBUT(Tear Film Break-up Time)|Change in conjunctival staining score	https://ClinicalTrials.gov/show/NCT02092207
66	NCT01960010	A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye	Completed	No Results Available	Dry Eye Syndromes	Drug: MIM-D3 Ophthalmic Solution|Drug: Vehicle	Mimetogen Pharmaceuticals USA, Inc.	Both	Adult|Senior	Phase 3	403	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	MIM-725	October 4, 2013	October 2013	August 2014	August 25, 2014	May 2014	No Study Results Posted	null	August 2014	Corneal Fluorescein Staining|Ocular Dryness|Total Ocular Fluorescein Staining|Ocular Discomfort	https://ClinicalTrials.gov/show/NCT01960010
67	NCT02254265	Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca	Active, not recruiting	No Results Available	Keratoconjunctivitis Sicca|Dry Eye Disease	Drug: OTX-101 0.05%|Drug: OTX-101 0.09%|Drug: Vehicle	Ocular Technologies SARL	Both	Adult|Senior	Phase 2|Phase 3	420	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	OTX-101-2014-001	September 29, 2014	September 2014	June 2015	April 21, 2015	April 2015	No Study Results Posted	null	May 2015	Conjunctival staining|Global symptom score|Tear film break up time (TBUT)|Clearing of corneal staining|Reduction in conjunctival staining|Change from baseline|Schirmers Test|Safety and tolerability	https://ClinicalTrials.gov/show/NCT02254265
68	NCT02121301	A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome	Completed	No Results Available	Keratoconjunctivitis Sicca	Drug: SkQ1|Drug: Placebo SkQ1 (Vehicle)	Mitotech, SA|ORA, Inc.	Both	Adult|Senior	Phase 2	90	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	13-110-0006	April 17, 2014	April 2014	null	July 21, 2014	July 2014	No Study Results Posted	null	May 2014	Fluorescein Staining|Worst Dry Eye Symptom	https://ClinicalTrials.gov/show/NCT02121301
69	NCT02139033	A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome	Completed	No Results Available	Keratoconjunctivitis Sicca	Drug: Retaine™	Ocusoft, Inc.|ORA, Inc.	Both	Adult|Senior	Phase 4	42	Industry	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	13-110-0008	May 6, 2014	May 2014	May 2014	June 10, 2014	June 2014	No Study Results Posted	null	May 2014	Tear Film Break-Up Time|Ocular surface damage as measured by fluorescein staining	https://ClinicalTrials.gov/show/NCT02139033
70	NCT01942226	Investigation on Medical Management of Dry Eye Patients	Completed	No Results Available	Dry Eye Syndrome		National Cheng Kung University|National Taiwan University Hospital|Sun-Huei Tseng Eye Institute|Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Tainan, Taiwan|Allergan Pharmaceuticals, Taipei, Taiwan	Both	Adult|Senior		466	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	MODE	September 10, 2013	August 2013	December 2013	December 6, 2013	December 2013	No Study Results Posted	null	November 2013	Artificial tears utilization patterns|Changes of dry eye symptoms, evaluated by clinicians|Changes of dry eye symptoms, evaluated by patients	https://ClinicalTrials.gov/show/NCT01942226
71	NCT01890941	A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes	Completed	No Results Available	Dry Eye Syndromes	Drug: KCT-0809 ophthalmic solution|Drug: Placebo	Kissei Pharmaceutical Co., Ltd.	Both	Adult|Senior	Phase 2	null	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study	KCT1205	June 27, 2013	null	null	October 16, 2015	October 2015	No Study Results Posted	null	March 2014	Score of the Corneal conjunctival staining|Incidences of Adverse Events	https://ClinicalTrials.gov/show/NCT01890941
72	NCT02117687	A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye	Completed	No Results Available	Dry Eye Syndromes|Keratoconjunctivitis Sicca	Drug: carboxymethylcellulose 0.5%/glycerin 0.9%|Drug: sodium hyaluronate 0.18%	Allergan	Both	Adult|Senior	Phase 4	80	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)	MAF-AGN-OPH-DE-016	April 16, 2014	April 2014	March 2015	April 9, 2015	April 2015	No Study Results Posted	null	January 2015	Change from Baseline in Global Ocular Staining Score|Change from Baseline in Ocular Surface Disease Index© (OSDI) Score	https://ClinicalTrials.gov/show/NCT02117687
73	NCT01833117	Efficacy and Safety Study of FID 119515A	Completed	Has Results	Dry Eye	Other: FID 119515A|Other: Blink® Tears	Alcon Research	Both	Adult|Senior		75	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	C-12-021	April 12, 2013	May 2013	June 2013	June 27, 2014	June 2014	May 29, 2014	null	June 2013	Mean Change From Baseline in Tear Break-up Time (TBUT) at 60 Minutes|Area Under Curve (AUC) of TBUT From 0 to 60 Minutes	https://ClinicalTrials.gov/show/NCT01833117
74	NCT02028312	A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®	Withdrawn	No Results Available	Dry Eye Disease	Drug: Loteprednol etabonate|Drug: Artificial Tears|Drug: Restasis	Edward Holland, MD|Holprovision	Both	Adult|Senior	Phase 4	0	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)	CEI.HER-002	January 3, 2014	January 2014	June 2016	March 17, 2015	March 2015	No Study Results Posted	null	February 2016	Fluorescein corneal staining scores|Lissamine green conjunctival staining	https://ClinicalTrials.gov/show/NCT02028312
75	NCT02199964	The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface	Recruiting	No Results Available	Dry Eye	Drug: Cyclosporin 0.05% emulsion|Drug: Endura, Refresh artificial tears	Baylor College of Medicine|Allergan	Both	Adult|Senior		30	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator)	H-33276	July 16, 2014	March 2014	June 2015	January 26, 2015	January 2015	No Study Results Posted	CsA	May 2015	Corneal fluorescein staining|eye irritation symptoms	https://ClinicalTrials.gov/show/NCT02199964
76	NCT02503189	A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome	Recruiting	No Results Available	Dry Eye With Sjögren's Syndrome	Drug: KCT-0809 ophthalmic solution|Drug: Placebo	Kissei Pharmaceutical Co., Ltd.	Both	Adult|Senior	Phase 3	null	Industry	Interventional		KCT1301	July 17, 2015	null	null	July 17, 2015	July 2015	No Study Results Posted	null	June 2017	Score of the corneal staining|Score of the conjunctival staining	https://ClinicalTrials.gov/show/NCT02503189
77	NCT02503163	A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome	Recruiting	No Results Available	Dry Eye With Sjögren's Syndrome	Drug: KCT-0809 ophthalmic solution	Kissei Pharmaceutical Co., Ltd.	Both	Adult|Senior	Phase 3	null	Industry	Interventional		KCT1303	July 17, 2015	null	null	July 17, 2015	July 2015	No Study Results Posted	null	April 2018	Incidences of adverse events|Score of the corneal staining	https://ClinicalTrials.gov/show/NCT02503163
78	NCT02503176	An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome	Recruiting	No Results Available	Dry Eye With Sjögren's Syndrome	Drug: KCT-0809 ophthalmic solution	Kissei Pharmaceutical Co., Ltd.	Both	Adult|Senior	Phase 3	null	Industry	Interventional		KCT1302	July 17, 2015	null	null	July 17, 2015	July 2015	No Study Results Posted	null	April 2018	Incidences of adverse events|Score of the corneal staining	https://ClinicalTrials.gov/show/NCT02503176
79	NCT02526290	Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator	Recruiting	No Results Available	Dry Eye Syndromes|Keratoconjunctivitis Sicca	Device: Intranasal Lacrimal Neurostimulator (Oculeve)	Oculeve, Inc.	Both	Adult|Senior		100	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care|Masking: Open Label	OCUN-010	August 14, 2015	August 2015	May 2016	September 2, 2015	September 2015	No Study Results Posted	null	May 2016	Stimulated acute tear production|Corrected distance visual acuity|Slit lamp biomicroscopy	https://ClinicalTrials.gov/show/NCT02526290
80	NCT01817582	Lotemax® Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis Sicca	Completed	No Results Available	Keratoconjunctivitis Sicca	Drug: Lotemax Gel + Restasis|Drug: Lotemax Gel|Drug: Restasis	Bausch & Lomb Incorporated	Both	Adult|Senior	Phase 2	102	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)	813	March 21, 2013	May 2013	March 2014	August 20, 2014	August 2014	No Study Results Posted	null	March 2014	Corneal fluorescein staining|Ocular Surface Disease Index|Worst Symptom Selection and Scoring|Ocular Comfort|Tear Osmolarity|Tear film break-up time (TFBUT)|Fluorescein Staining|Lissamine green (LG) stain|Dry eye signs and symptoms|Eye Redness|Anesthetized Schirmer's Test|Global Improvement in Dry Eye	https://ClinicalTrials.gov/show/NCT01817582
81	NCT02072122	Estrogen and the Outer Eye in Women During Fertility Treatment	Not yet recruiting	No Results Available	Dry Eye Syndromes		Meir Medical Center	Female	Adult		30	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	EOEDFT-2	February 24, 2014	March 2014	July 2014	February 25, 2014	February 2014	No Study Results Posted	null	June 2014	Evidence of clinically definite dry eye confirmed by Schirmer test and tear break up time test|Evidence of clinically definite dry eye confirmed by Schirmer test and tear break up time test during each on of the meetings #1,#2 (day 0, day 10)	https://ClinicalTrials.gov/show/NCT02072122
82	NCT02424266	Three Dimension Tomography of Eye Structures by White Light Imaging Device	Not yet recruiting	No Results Available	Healthy Subjects|Moderate to Severe Keratoconjunctivitis Sicca (KCS)|Dry Eye Syndrome (DES)	Device: None invasive imaging of the tear film (AdOM)	Meir Medical Center	Both	Adult|Senior		60	Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	MMC-0166-13	April 1, 2015	April 2015	June 2016	April 22, 2015	April 2015	No Study Results Posted	3D-WLT	December 2015	Safety (Ocular symptoms)|Imaging capabilities (field of view, resolution)|Tear film measurements (lipid layer thickness, aqueous layer thickness)	https://ClinicalTrials.gov/show/NCT02424266
83	NCT01854905	An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusis (LASIK) Therapy	Completed	Has Results	Dry Eye Syndromes	Other: No Treatment	Allergan	Both	Adult|Senior		400	Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	MAF-AGN-OPH-DE-015	May 14, 2013	May 2013	September 2013	January 28, 2014	January 2014	January 28, 2014	null	September 2013	Percentage of Patients in Each Category of the Dry Eye Workshop Severity (DEWS) Scale	https://ClinicalTrials.gov/show/NCT01854905
84	NCT02028754	A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms	Completed	Has Results	Dry Eye Syndromes|Cataract	Drug: Sodium Carboxymethylcellulose|Drug: Levofloxacin|Drug: Prednisolone	Allergan	Both	Adult|Senior	Phase 4	180	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	CN-CMC-1101	January 6, 2014	July 2011	May 2013	March 19, 2014	March 2014	March 19, 2014	RLOTUS	May 2013	Tear Break-Up Time (TBUT) in the Study Eye|Fluorescein Staining Score in the Study Eye|Lissamine Green Staining Score in the Study Eye|Results of Schirmer I Test With Anesthetics in the Study Eye|Ocular Surface Disease Index (OSDI) Questionnaire Score in the Study Eye|Subjective Symptom Total Score in the Study Eye	https://ClinicalTrials.gov/show/NCT02028754
85	NCT02280473	A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease	Completed	No Results Available	Dry Eye Syndromes	Drug: Carboxymethylcellulose Sodium Based Eye Drop|Drug: Carboxymethylcellulose Sodium 1.0%	Allergan	Both	Adult|Senior	Phase 3	188	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	11193X-001	October 29, 2014	October 2014	March 2015	May 4, 2015	May 2015	No Study Results Posted	null	March 2015	Change from Baseline in the Ocular Surface Disease Index© (OSDI©) Score on a 5-Point Scale|Change from Baseline in Tear Break-up Time (TBUT)|Change from Baseline in Corneal Staining on a 6-Point Scale|Change from Baseline in Conjunctival Staining on a 6-Point Scale|Change from Baseline in the Schirmer Test	https://ClinicalTrials.gov/show/NCT02280473
86	NCT02553772	A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.	Not yet recruiting	No Results Available	Dry Eye Syndromes	Drug: Carboxymethylcellulose Based Eye Drop|Drug: Carboxymethylcellulose Sodium 0.5%	Allergan	Both	Adult|Senior	Phase 3	242	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	11182X-001	September 16, 2015	November 2015	June 2016	September 16, 2015	September 2015	No Study Results Posted	null	June 2016	Change from Baseline in the Ocular Surface Disease Index© (OSDI©) Score on a 5-Point Scale|Change from Baseline in Tear Break-up Time (TBUT)|Change from Baseline in Corneal Staining on a 6-Point Scale|Change from Baseline in Conjunctival Staining on a 6-Point Scale|Change from Baseline in the Schirmer Test	https://ClinicalTrials.gov/show/NCT02553772
87	NCT01882413	A Study to Determine the Prevalence of Inflammatory Dry Eye Disease in Patients Prior to Cataract Removal	Completed	No Results Available	Dry Eye Syndromes	Other: No intervention	Allergan	Both	Adult|Senior		204	Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	GMA-RES-012-001	June 18, 2013	June 2013	March 2014	April 15, 2014	April 2014	No Study Results Posted	REVEAL	March 2014	Percentage of Patients with a Presence of Matrix Metalloproteinase-9 (MMP-9) in the Study Eye|Subject Evaluation of Symptoms of Dryness on a 5-Point Scale|Ocular Surface Disease Index© (OSDI©) Questionnaire Score|Tear Film Break-up Time (TFBUT)|Corneal Staining on a 6-Point Scale|Conjunctival Staining on a 6-Point Scale|Tear Wetting Using Schirmer's test|Artificial Tear Use|History of Punctal Plug Use	https://ClinicalTrials.gov/show/NCT01882413
88	NCT02013791	Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease	Recruiting	No Results Available	Dry Eye Syndromes	Drug: Placebo|Other: Sham|Drug: Cyclosporine New Ophthalmic Formulation	Allergan	Both	Adult|Senior	Phase 2	138	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	192371-024	December 12, 2013	April 2014	July 2017	October 7, 2015	October 2015	No Study Results Posted	null	July 2017	Corneal Staining Score Using a 6-Point Scale	https://ClinicalTrials.gov/show/NCT02013791
89	NCT02420730	Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye	Recruiting	No Results Available	Healthy Volunteers|Dry Eye Syndromes	Drug: AGN-232411|Drug: AGN-232411 Vehicle	Allergan	Both	Adult|Senior	Phase 1	72	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	232411-001	April 15, 2015	June 2015	June 2016	August 5, 2015	August 2015	No Study Results Posted	null	June 2016	Percentage of Participants with Treatment Emergent Adverse Events (TEAEs)	https://ClinicalTrials.gov/show/NCT02420730
90	NCT02435914	Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease	Recruiting	No Results Available	Dry Eye Syndromes	Drug: AGN-223575 ophthalmic solution|Drug: AGN-223575 vehicle ophthalmic solution	Allergan	Both	Adult|Senior	Phase 2	168	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	223575-002	May 1, 2015	June 2015	December 2016	July 27, 2015	July 2015	No Study Results Posted	null	November 2016	Change from Baseline in Conjunctival Redness Score Using a 5-Point Scale|Change from Baseline in Ocular Surface Disease Index (OSDI) Score Using a 5-Point Scale|Change from Baseline in Corneal Staining Score Using a 6-Point Scale|Complete Redness Response (Yes/No) in the Study Eye	https://ClinicalTrials.gov/show/NCT02435914
91	NCT02455050	A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief	Recruiting	No Results Available	Dry Eye Syndromes	Drug: Carboxymethylcellulose Sodium Based Eye Drops|Drug: Systane® Gel Drops|Drug: Genteal® Lubricant Gel Drops	Allergan	Both	Adult|Senior	Phase 3	84	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)	11193X-002	January 22, 2015	December 2014	November 2015	September 28, 2015	September 2015	No Study Results Posted	null	November 2015	Tolerability Survey Score Using a 100 Unit Visual Analog Scale (VAS)|Ocular Surface Disease Index© (OSDI©) Score Using a 5-Point Scale|Acceptability Survey Score Using a 5-Point Scale|Subjective Evaluation of Symptoms of Dryness (SESoD) Score Using a 5-Point Scale|End of Study Survey: Assessing Comfort, Blur, and Relief of Symptoms|Distance Visual Acuity|Tear Break-Up Time with Fluorescein|Eye Drop Experience Survey Score: Assessing Vision, Comfort, and Relief of Symptoms	https://ClinicalTrials.gov/show/NCT02455050
92	NCT02385292	Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation	Recruiting	No Results Available	Dry Eye Syndromes	Device: Oculeve Intranasal Lacrimal Neurostimulator	Oculeve, Inc.	Both	Adult|Senior		35	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Outcomes Assessor)	OCUN-003	March 2, 2015	May 2015	February 2016	October 13, 2015	October 2015	No Study Results Posted	null	December 2015	Fluorescein tear clearance with application	https://ClinicalTrials.gov/show/NCT02385292
93	NCT02298881	Ocular Surface Microbiome	Recruiting	No Results Available	Dry Eye Syndromes		University of Washington|National Institutes of Health (NIH)|National Eye Institute (NEI)	Both	Adult|Senior		80	Other|NIH	Observational	Observational Model: Case Control|Time Perspective: Prospective	43018-B|1R01EY022038-01A1	November 18, 2014	July 2013	June 2017	November 19, 2014	November 2014	No Study Results Posted	null	June 2017	To catalog the bacteria and other micro-organisms that are naturally found on the eye surface.	https://ClinicalTrials.gov/show/NCT02298881
94	NCT01863368	Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining	Completed	Has Results	Dry Eye Syndrome	Other: Preservative-free saline solution eyedrops|Other: Systane® ULTRA lubricant eyedrops|Other: OPTIVE® lubricating eyedrops	Alcon Research	Both	Adult|Senior		105	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	M-12-040	May 23, 2013	September 2013	June 2014	July 9, 2015	July 2015	June 17, 2015	null	June 2014	Mean Change From Baseline in Total Ocular Surface Staining (TOSS) Score at Day 35 (Phase I)|Mean Ocular Surface Disease Index (OSDI) Score at Day 35 (Phase I)|Mean Impact of Dry Eye on Everyday Life (IDEEL) Treatment Effectiveness Score at Day 35 (Phase I)|Mean Impact of Dry Eye on Everyday Life (IDEEL) Treatment Inconvenience Score at Day 35 (Phase I)	https://ClinicalTrials.gov/show/NCT01863368
95	NCT02031172	Effects of Sustained Reading on the Ocular Surface	Recruiting	No Results Available	Dry Eye Syndromes|Sjogren's Syndrome		University of Rochester	Both	Adult|Senior		40	Other	Observational	Observational Model: Case Control|Time Perspective: Cross-Sectional	00048640	December 2, 2013	March 2014	January 2017	April 27, 2015	April 2015	No Study Results Posted	null	April 2016	To see if changes in visual reading function correlate with changes in optical and retinal image quality, secondary to changes in tear film dynamics|To determine whether corneal sensation and corneal nerve morphology correlate with sustained reading function	https://ClinicalTrials.gov/show/NCT02031172
96	NCT01900249	To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca	Completed	No Results Available	Keratoconjunctivitis Sicca	Drug: R348 Ophthalmic Solution, 0.2%|Drug: R348 Ophthalmic Solution, 0.5%|Drug: Placebo	Rigel Pharmaceuticals	Both	Adult|Senior	Phase 2	206	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	C-932348-003	July 11, 2013	July 2013	July 2014	July 11, 2014	July 2014	No Study Results Posted	DROPS	July 2014	Change of inferior corneal fluorescein staining score.	https://ClinicalTrials.gov/show/NCT01900249
97	NCT02161341	Ocular Surface Microbiome in Dry Eye Patients	Recruiting	No Results Available	Dry Eye		Singapore National Eye Centre	Both	Adult|Senior		90	Other	Observational	Observational Model: Case Control|Time Perspective: Cross-Sectional	R1146/48/2014|2014/520/A	June 9, 2014	June 2014	July 2015	May 18, 2015	June 2014	No Study Results Posted	null	July 2015	bacterial microbiome|Gene expression|Clinical characteristic	https://ClinicalTrials.gov/show/NCT02161341
98	NCT02066051	IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD	Completed	No Results Available	GVHD|Ocular Rosacea|Dry Eye Syndrome	Device: IPL	Mayo Clinic	Both	Adult|Senior		8	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	13-003814	February 13, 2014	October 2013	November 2014	May 27, 2015	May 2015	No Study Results Posted	null	November 2014	Number of participants who respond to IPL|Number of participants who experience adverse events	https://ClinicalTrials.gov/show/NCT02066051
99	NCT02455999	Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain	Recruiting	No Results Available	Ocular Pain|Dry Eye Syndrome	Drug: SYL1001|Drug: SYL1001|Drug: Placebo	Sylentis, S.A.	Both	Adult|Senior	Phase 2	60	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	SYL1001_III	May 20, 2015	June 2015	null	August 5, 2015	August 2015	No Study Results Posted	null	March 2016	Change from the baseline scoring of eye pain on the Visual Analogue Scale (VAS)|Change from the baseline scoring of ocular discomfort in the Ocular Surface Disease Index (OSDI)|Change from the baseline scoring after fluorescein staining of the cornea|Frequency of occurrence of conjunctival hyperaemia|Change from baseline in vital signs|Change from baseline in standard laboratory parameters|Assessment of Adverse Events (AEs) as a measure of SYL1001 safety|Change from baseline in standard ocular parameters	https://ClinicalTrials.gov/show/NCT02455999
100	NCT01970917	Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects	Completed	No Results Available	Dry Eye Syndrome|Healthy	Device: Olixia pure eye drops|Device: Placebo	Medical University of Vienna	Both	Adult|Senior	Phase 4	16	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	OPHT-190313	July 11, 2013	October 2013	November 2013	November 26, 2013	November 2013	No Study Results Posted	null	November 2013	Tear film thickness	https://ClinicalTrials.gov/show/NCT01970917
101	NCT02356341	NovaTears® Eye Drops Observational Study NT-002	Recruiting	No Results Available	Dry Eye Syndromes	Device: NovaTears® Eye Drops	Novaliq GmbH	Both	Adult|Senior		90	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	NT-002	January 21, 2015	January 2015	December 2015	August 19, 2015	August 2015	No Study Results Posted	null	December 2015	Subjective symptom severity|Tear-Film Break-up Time	https://ClinicalTrials.gov/show/NCT02356341
102	NCT02356328	NovaTears® Eye Drops Observational Study NT-003	Recruiting	No Results Available	Dry Eye Syndromes	Device: NovaTears® Eye Drops	Novaliq GmbH	Both	Adult|Senior		30	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	NT-003	January 21, 2015	January 2015	December 2015	August 19, 2015	August 2015	No Study Results Posted	null	December 2015	Subjective symptom severity|Tear-Film Break-up Time	https://ClinicalTrials.gov/show/NCT02356328
103	NCT02315079	Point of Care Testing of Inflammatory Markers in Tears	Recruiting	No Results Available	Dry Eye Syndrome	Other: Eye inflammation|Other: Without eye inflammation	University of Florida	Both	Adult|Senior		300	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	IRB201400775	December 9, 2014	January 2015	January 2017	August 3, 2015	August 2015	No Study Results Posted	null	January 2017	Measurement of matrix metalloproteinase-9 in tears	https://ClinicalTrials.gov/show/NCT02315079
104	NCT02100787	Changes in Tear Osmolarity Over Time With Sustained Use of TheraTears	Not yet recruiting	No Results Available	Dry Eye Syndrome	Other: TheraTears lubricating drops	Jenkins Eye Care|Advanced Vision Research	Both	Adult|Senior		35	Other|Industry	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	AVR_PM_102_13	March 27, 2014	April 2014	July 2015	March 27, 2014	March 2014	No Study Results Posted	BENTLEY	April 2015	Change in tear osmolarity|Change in the Ocular Surface Disease Index (OSDI) score|Change in visual acuity|Change in Tear Break Up Time|Change in Phenol Red Thread test|Change in corneal and conjunctival staining	https://ClinicalTrials.gov/show/NCT02100787
105	NCT01808560	Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery	Completed	No Results Available	Blepharitis|Dry Eye Syndrome	Device: LipiFlow Pre-Treatment|Device: LipiFlow Post-treatment	TearScience, Inc.	Both	Adult|Senior		34	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label	LF005	March 7, 2013	March 2013	January 2015	February 4, 2015	February 2015	No Study Results Posted	null	January 2015	Mean change in total meibomian gland score|Mean change in Ocular Surface Disease Index (OSDI) questionnaire score	https://ClinicalTrials.gov/show/NCT01808560
106	NCT02554981	Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®	Recruiting	No Results Available	Dry Eye Syndromes	Drug: Cyclosporine 0.05% Ophthalmic Emulsion	Allergan	Both	Adult	Phase 4	50	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	MA-RES-015-001	September 17, 2015	July 2015	July 2016	September 17, 2015	September 2015	No Study Results Posted	EMPOWER	July 2016	Visual Function|Ocular Surface Staining Score|Ocular Protection Index|Diurnal Blink Rate|Ocular Symptoms Questionnaire Score	https://ClinicalTrials.gov/show/NCT02554981
107	NCT02121847	Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy	Completed	No Results Available	Dry Eye Syndromes	Drug: cyclosporine 0.05% ophthalmic emulsion|Drug: carboxymethylcellulose-based lubricant eye drops	Allergan	Both	Adult|Senior	Phase 4	40	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	GMA-RES-014-001	April 22, 2014	April 2014	September 2014	March 16, 2015	March 2015	No Study Results Posted	IMPACT	September 2014	Visual Function Reading Speed|Tear Film Break-up Time (TFBUT)|Ocular Protection Index|Conjunctival Redness Score|Ocular Surface Staining Score|Blink Rate|Ocular Symptoms Questionnaire Score	https://ClinicalTrials.gov/show/NCT02121847
108	NCT01840787	A Pilot Study on the Use of a Sensory Panel to Assess Comfort Between Three Different Contact Lenses	Completed	No Results Available	Dry Eye Syndromes	Device: balafilcon A (8.6)|Device: balafilcon A (8.3)|Device: senofilcon A	University of Waterloo|Alcon Research	Both	Child|Adult|Senior		63	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)	P/433/12/IIS-L	April 19, 2013	April 2013	January 2014	July 9, 2014	July 2014	No Study Results Posted	NAISMITH	January 2014	Change in eye comfort ratings	https://ClinicalTrials.gov/show/NCT01840787
109	NCT02470429	Evaluation of Clinical Outcomes After the Use of SYSTANE® HYDRATION	Recruiting	No Results Available	Dry Eye	Device: SYSTANE HYDRATION lubricant eye drops|Device: Hyabak 0.15% eye drops|Drug: 0.9% saline eye drops	Alcon Research	Both	Adult|Senior		100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	EXK947-P001	June 10, 2015	July 2015	August 2016	July 20, 2015	July 2015	No Study Results Posted	null	August 2016	Change from Baseline in Total Ocular Surface Staining (TOSS) Score at Day 42|Change from Baseline in IDEEL Treatment Satisfaction Scores (effectiveness and inconvenience) at Day 42|Change from Baseline in Tear Film Break-up Time (TFBUT) at Day 42	https://ClinicalTrials.gov/show/NCT02470429
110	NCT02123147	Examining the Immunological Process of Autoimmune Patients	Recruiting	No Results Available	Sjogren's Syndrome|Autoimmune Diseases|Dry Eyes|Dry Mouth		University of Florida	Both	Child|Adult		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	IRB201400079	April 16, 2014	July 2014	July 2017	June 9, 2015	June 2015	No Study Results Posted	null	July 2017	Receptor gene rearrangement.|Receptor gene rearrangement	https://ClinicalTrials.gov/show/NCT02123147
111	NCT02148497	Multi-Colored Placido Disk Viability	Active, not recruiting	No Results Available	Dry Eye|Sjogren's Disease|Healthy	Procedure: Multi-colored Placido disk imaging	University of Rochester	Both	Adult|Senior		20	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label	51771	April 15, 2014	May 2014	September 2016	September 18, 2015	September 2015	No Study Results Posted	null	September 2016	Tear film break-up time	https://ClinicalTrials.gov/show/NCT02148497
112	NCT02217137	Tear Proteins, Conjunctival Cells and Imaging Eyes in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients	Recruiting	No Results Available	Dry Eye		Singapore National Eye Centre	Both	Adult|Senior		80	Other	Observational	Observational Model: Case Control|Time Perspective: Cross-Sectional	R1108/10/2014|2014/269/A	June 9, 2014	June 2014	July 2015	May 18, 2015	June 2014	No Study Results Posted	null	July 2015	Profile tear cytokines|Profile immune response	https://ClinicalTrials.gov/show/NCT02217137
113	NCT01933165	Reproducibility of LipiView Ocular Surface Interferometer (LipiView) for Measuring Tear Lipid Layer Thickness	Completed	No Results Available	Dry Eyes	Device: LipiView	Singapore National Eye Centre	Both	Adult|Senior		20	Other	Interventional	Intervention Model: Single Group Assignment|Masking: Open Label	R1028/43/2013|2013/327/A	August 28, 2013	September 2013	February 2014	June 9, 2014	June 2014	No Study Results Posted	null	February 2014	The repeatability of objective tear lipid layer thickness measurements of LipiView from the same examiner.	https://ClinicalTrials.gov/show/NCT01933165
114	NCT02481167	Evaluation of Meibomian Gland Dysfunction in Chinese Old Patients	Recruiting	No Results Available	Dry Eye		Wenzhou Medical University	Both	Adult|Senior		100	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	WZ-ZYY-DRYEYE	June 15, 2015	January 2015	January 2018	June 24, 2015	June 2015	No Study Results Posted	null	April 2016	Tear film break-up time|Lower tear meniscus|The morphology of meibomian glands	https://ClinicalTrials.gov/show/NCT02481167
115	NCT01991132	Validating the Diagnostic Accuracy of Mediview 2.0 Software as an Image Analysis Tool of Meibomian Glands	Completed	No Results Available	Dry Eyes	Other: MediView 2.0 software	Singapore National Eye Centre	Both	Adult|Senior		100	Other	Interventional	Intervention Model: Single Group Assignment|Masking: Open Label	R1059/74/2013|2013/737/A	November 11, 2013	December 2013	December 2014	May 18, 2015	June 2014	No Study Results Posted	null	December 2014	To certify the accuracy of the software	https://ClinicalTrials.gov/show/NCT01991132
116	NCT01933178	Reproducibility of Anterior Segment Optical Coherence Tomography (AS-OCT) for Imaging Conjunctivochalasis	Completed	No Results Available	Dry Eyes	Device: Cirrus AS-OCT	Singapore National Eye Centre	Both	Adult|Senior		20	Other	Interventional	Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label	R1029/44/2013|2013/328/A	August 28, 2013	September 2013	February 2014	June 9, 2014	June 2014	No Study Results Posted	null	February 2014	The repeatabilty of objective conjunctivochalasis measurements of HD-Cirrus AS-OCT from the same examiner, and between the two examiners	https://ClinicalTrials.gov/show/NCT01933178
117	NCT02066896	Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome	Recruiting	No Results Available	KERATOCONJUNCTIVITIS SICCA|XEROSTOMIA|SICCA SYNDROME|PRIMARY SJOGREN SYNDROME	Device: Laser 3R 790nm infrared Ga AIAs|Device: Laser 3R 790 nm infrared GaAIAs	Federal University of São Paulo	Both	Adult|Senior	Phase 2	34	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	LLLXS	August 15, 2013	January 2014	August 2014	February 19, 2014	February 2014	No Study Results Posted	null	June 2014	The xerostomia inventory|salivary analysis by proteomic|Salivary flux measurement	https://ClinicalTrials.gov/show/NCT02066896
118	NCT02234635	Visual Quality Change of Eyes Implanted With Diffractive Multifocal Intraocular Lens After Cataract Surgery	Recruiting	No Results Available	Dry Eye|Vision Disorders|Quality of Life	Other: Diffractive multifocal IOLs group	Wenzhou Medical University	Both	Adult|Senior		50	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	VQIOL-21	July 31, 2014	August 2012	February 2015	September 8, 2014	September 2014	No Study Results Posted	null	September 2014	To evaluate the Visual Quality Change of Eyes Implanted With Diffractive Multifocal Intraocular Lens|To evaluate the Tear-film Quality Dynamics of Eyes Implanted With Diffractive Multifocal Intraocular Lens	https://ClinicalTrials.gov/show/NCT02234635
119	NCT02160769	Tear Layer Lipid Thickness in Pterygium Patient Before and After Surgery	Recruiting	No Results Available	Dry Eye		Singapore National Eye Centre	Both	Adult|Senior		80	Other	Observational	Observational Model: Case Control|Time Perspective: Prospective	R1075/90/2013|2013/851/A	June 9, 2014	November 2013	December 2015	May 18, 2015	June 2014	No Study Results Posted	null	December 2015	tear lipid layer thickness	https://ClinicalTrials.gov/show/NCT02160769
120	NCT02493244	Lipid Layer Thickness Pre and Post Lid Scrubs With Cliradex	Recruiting	No Results Available	Dry Eye	Other: Cliradex	University of Waterloo|Canadian Optometric Education Trust Fund (COETF)	Both	Child|Adult|Senior		20	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label	20714	June 8, 2015	June 2015	December 2015	July 6, 2015	July 2015	No Study Results Posted	HONDA	December 2015	Lipid layer thickness|Non-invasive tear breakup time (NITBUT)|Dry Eye Questionnaire (SPEED score)|Overall corneal staining grade|Conjunctival hyperemia	https://ClinicalTrials.gov/show/NCT02493244
121	NCT02005874	A Study To Investigate The Effects Of A Low Humidity Environment And Visual Tasking On Tear Film Protein Composition	Completed	No Results Available	Dry Eye		Inflamax Research Incorporated	Both	Adult|Senior		16	Industry	Observational	Observational Model: Case Control|Time Perspective: Prospective	13-RD-01|EGP #445977-12	November 28, 2013	November 2013	November 2013	December 6, 2013	December 2013	No Study Results Posted	null	November 2013	Change in Tear Protein and/or Cytokine Composition|Clinical and Subjective Sign and Symptom Scores	https://ClinicalTrials.gov/show/NCT02005874
122	NCT02111928	NovaTears® Eye Drops Observational Study	Completed	No Results Available	Dry Eye Disease	Device: NovaTears® Eye Drops	Novaliq GmbH	Both	Adult|Senior		30	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	NT-001	April 7, 2014	December 2013	May 2014	October 5, 2015	October 2015	No Study Results Posted	null	May 2014	Efficacy measured by routine ophthalmological assessment|Local Tolerability measured by ophthalmological assessment	https://ClinicalTrials.gov/show/NCT02111928
123	NCT02554084	Optical Coherence Tomography of Tear Film Dynamics In-Vivo	Recruiting	No Results Available	Dry Eye Disease	Device: Optical Coherence Tomography	University of Rochester	Both	Adult|Senior		60	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label	52165	November 24, 2014	November 2014	September 2016	September 16, 2015	September 2015	No Study Results Posted	null	September 2016	Thickness of lipid layers on patient cornea (nm)|Thickness of aqueous layers on patient cornea (um)|Thickness maps dynamics|Optical aberrations	https://ClinicalTrials.gov/show/NCT02554084
124	NCT02040623	Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)	Recruiting	No Results Available	Chronic Graft-versus-host Disease	Drug: R348 Ophthalmic Solution, 0.2%|Drug: R348 Ophthalmic Solution, 0.5%|Other: Placebo Ophthalmic Solution	Rigel Pharmaceuticals	Both	Adult|Senior	Phase 2	60	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	C-932348-004	January 16, 2014	March 2014	December 2015	July 17, 2015	July 2015	No Study Results Posted	DROPS-2	December 2015	Mean change of total Corneal fluorescein staining score	https://ClinicalTrials.gov/show/NCT02040623
125	NCT02260973	The Influence of PRN Omega-3 Nutritional Supplement on Visual Acuity	Recruiting	No Results Available	Cataract, Dry Eye Disease	Dietary Supplement: Omega-3 (Triglyceride form)	Physician Recommended Nutriceuticals	Both	Adult|Senior	Phase 2|Phase 3	150	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	PRN 20145	October 6, 2014	November 2014	null	June 5, 2015	June 2015	No Study Results Posted	null	April 2016	Visual Acuity	https://ClinicalTrials.gov/show/NCT02260973
126	NCT02501187	Risk of Dry Eye Post Different Surgeries for Blepharoptosis Repair	Not yet recruiting	No Results Available	Blepharoptosis	Procedure: Levator advancement|Procedure: Müller's muscle-conjunctival resection procedure|Procedure: White line advancement	Rabin Medical Center	Both	Adult|Senior		75	Other	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	Ptosis-01	July 12, 2015	July 2015	null	July 15, 2015	July 2015	No Study Results Posted	null	July 2017	Diagnosis of objective or subjective deterioration in dry eye status|Ptosis repair procedure success	https://ClinicalTrials.gov/show/NCT02501187
127	NCT01947517	The Retention Rate Between Brand A and Brand B Punctal Plugs	Recruiting	No Results Available	Moderate to Severe Dry Eye	Device: Parasol Punctal Occluder|Device: Superflex Punctal Occluder	Queen's University	Both	Child|Adult|Senior		50	Other	Observational	Time Perspective: Prospective	Punctal plugs	September 17, 2013	September 2013	August 2014	September 26, 2013	September 2013	No Study Results Posted	null	May 2014	Length of retention|Improvement in Canadian Dry Eye Assessment scores|Improvement in corneal fluorescein staining|Improvement in lissamine green conjunctival staining|Improvement in tear meniscus height	https://ClinicalTrials.gov/show/NCT01947517
128	NCT02203188	Effect of Debridement-scaling on the Relief of Dry Eye Signs and Symptoms in Sjogren's Syndrome	Completed	No Results Available	Sjogren's Syndrome	Procedure: Lid debridgement scaling	University of Waterloo|Sjogren's Society of Canada	Both	Child|Adult|Senior		14	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	20000	July 25, 2014	August 2014	November 2014	December 18, 2014	December 2014	No Study Results Posted	TOYOTA	November 2014	Meibomian gland score (MGS)|SICCA Ocular Staining Score|Ocular Surface Disease Index Score (OSDI)|Meibomian gland yielding liquid secretions (MGYLS)|Symptom Assessment iN Dry Eye score	https://ClinicalTrials.gov/show/NCT02203188
129	NCT01870180	EyeBag Effectiveness in Meibomian Gland Dysfunction	Completed	No Results Available	Meibomian Gland Dysfunction	Device: EyeBag|Other: Placebo	Aston University	Both	Adult|Senior		18	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)	2013MGD	May 24, 2013	May 2013	December 2014	January 14, 2015	January 2015	No Study Results Posted	MGD	July 2013	Change in Ocular Symptoms|Change in Tear Film Quality|Change in Ocular redness|Change in Lipid layer thickness|Change in Meibomian Glands	https://ClinicalTrials.gov/show/NCT01870180
130	NCT02212301	Comparison of Two Marketed Lenses in a Controlled Environment	Completed	No Results Available	Eye Dryness	Device: senofilcon A|Device: AIR OPTIX® AQUA	Vistakon	Both	Adult		100	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)	CR-5573	August 7, 2014	July 2014	December 2014	February 10, 2015	February 2015	No Study Results Posted	null	December 2014	Tear Film Kinetics|Time Controlled Visual Acuity	https://ClinicalTrials.gov/show/NCT02212301
131	NCT01807689	Salivary Biomarkers for Sjögren's Syndrome Detection	Recruiting	No Results Available	Sjögren's Syndrome		University of California, Los Angeles|Oklahoma Medical Research Foundation|University of Minnesota - Clinical and Translational Science Institute|University Medical Center Groningen	Both	Adult|Senior		420	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	SS Biomarker Development Study	February 21, 2013	April 2013	April 2018	December 1, 2014	December 2014	No Study Results Posted	null	April 2018	With a PRoBE design, build an initial collective salivary biomarker panel to evaluate its ability to diagnose a Sjogrenn Syndrome (SS) patient.|Test the second 210 recruited subjects, refine and evaluate the collective saliva biomarker panel on entire 420 subjects.	https://ClinicalTrials.gov/show/NCT01807689
132	NCT01942642	Evaluation of Dry Eye and Meibomian Gland Dysfunction After Cataract Surgery	Completed	No Results Available	Meibomian Gland Dysfunction		Yonsei University	Both	Adult|Senior		48	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	4-2012-0690	August 29, 2013	November 2012	April 2013	September 13, 2013	September 2013	No Study Results Posted	null	April 2013	Ocular parameters	https://ClinicalTrials.gov/show/NCT01942642
133	NCT02149615	Antiacne Medications Pseudotumor Cerebri	Recruiting	No Results Available	Optic Disc Swelling	Other: Retinal nerve fibre layer measurement	University of Zurich|University Hospital, Zürich	Both	Adult|Senior	Phase 4	310	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	KEK-ZH 2013-0433 AAMPTC|2013DR4066	April 7, 2014	April 2014	December 2019	May 26, 2014	May 2014	No Study Results Posted	AAMPTC	April 2019	Retinal nerve fibre layer	https://ClinicalTrials.gov/show/NCT02149615
134	NCT02114073	Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Success of Trabeculectomy Procedure	Completed	No Results Available	Glaucoma, Open Angle	Drug: Cyclosporine|Drug: Betamethasone	Mashhad University of Medical Sciences	Both	Adult|Senior	Phase 2	40	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	MUMS-911251|IRCT138706111154N1	April 6, 2014	April 2014	February 2015	April 17, 2015	April 2015	No Study Results Posted	BCATS	November 2014	Intraocular Pressure (IOP)|Bleb morphology|Subjective dry eye symptoms|Surgical success rate|Complications|Visual acuity	https://ClinicalTrials.gov/show/NCT02114073
135	NCT01787942	Investigating Abnormal Lipid Layer Thickness in Blepharoplasty Patients	Completed	No Results Available	Lipid Thickness	Device: Tear Science LipiView	Singapore National Eye Centre	Both	Adult|Senior		60	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label	R974/83/2012|2012/975/A	February 7, 2013	January 2013	March 2014	August 15, 2014	February 2013	No Study Results Posted	null	March 2014	Lipid layer thickness|Tear break up time|Fluorescein Dye Corneal Staining	https://ClinicalTrials.gov/show/NCT01787942
136	NCT02049112	A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study	Completed	No Results Available	Xerostomia|Hyposalivation|Head and Neck Cancer|Sjögren Syndrome	Device: Salivary equivalent|Device: Aequasyal|Device: Biotene	Unither Pharmaceuticals, France	Both	Adult|Senior	Phase 4	210	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label	UN/2011/001	January 27, 2014	January 2012	June 2013	January 27, 2014	January 2014	No Study Results Posted	NIAGARA	April 2013	Dry mouth discomfort|Mouth burning sensation|Speech difficulties|Chewing difficulties|Swallowing difficulties|Taste perversion|Medical device acceptability|Medical device safety assessment	https://ClinicalTrials.gov/show/NCT02049112
137	NCT02322528	Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax	Completed	Has Results	Sjogren's Disease	Drug: Administration of Lotemax	University of Rochester|Bausch & Lomb Incorporated	Both	Adult|Senior		10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label	47817	April 16, 2014	April 2014	August 2015	September 17, 2015	September 2015	September 17, 2015	null	August 2015	Ocular Surface Temperature of Both Eyes|Visual Quality	https://ClinicalTrials.gov/show/NCT02322528
138	NCT02112019	Endoscopic Treatment of Salivary Glands Affected by Sjögren's Syndrome	Recruiting	No Results Available	Sjögren's Syndrome	Procedure: Sialoendoscopy|Drug: saline|Drug: hydrocortisone	Derk Jan Jager|VU University Medical Center	Both	Adult|Senior		60	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Single Blind (Subject)	NL44018.029.13	April 8, 2014	June 2014	December 2016	June 3, 2014	June 2014	No Study Results Posted	null	December 2014	Change, compared to baseline and to a non-treatment control group, in unstimulated whole mouth saliva in ml/min after sialoendoscopic treatment|Change, compared to baseline and to a non-treatment control group, in the stimulated parotid salivary flow after performing sialoendoscopic rinsing (with or without hydrocortisone)|Change in mouthfeel score (XI score)|Change in the EULAR SS Patient Reported Index score|Change in the CODS score	https://ClinicalTrials.gov/show/NCT02112019
139	NCT02495129	Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome	Not yet recruiting	No Results Available	Primary Sjögren's Syndrome	Drug: VAY736 lower dose|Drug: VAY736 higher dose	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 1|Phase 2	25	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	CVAY736X2103	July 8, 2015	November 2015	August 2017	July 10, 2015	July 2015	No Study Results Posted	null	August 2017	Part 1: To determine the feasibility of measuring major salivary gland infiltrating B cells in pSS patients using [Zr- 89]rituximab PET/CT imaging|Part 2: To define the normal range of PET/CT imaging values for major salivary gland tissue, cervical lymph nodes and spleen in healthy volunteers with [Zr-89]-rituximab|Part 3: To compare the effect of two different VAY736 s.c. dose regimes on salivary gland-infiltrating B cells in pSS patients, using [Zr-89]-rituximab PET/CT imaging|Safety of multiple s.c. dosing of VAY736 in pSS patients as measured by safety assessments|To assess the pharmacokinetiks of VAY736 in pSS patients Area under the curve (AUC)|To assess the pharmacokinetiks of VAY736 in pSS patients Trough concentrations|Assess the pharmacodynamic effect of VAY736 on circulating CD19+ B-cells in pSS (depletion of B cells)|Assess effect of two different VAY736 dose levels on target tissue structure and function in pSS (size of spleen and cervical lyph nodes by PET/CT imaging and ultrasound-aided size measurements)|Assess effect of two different VAY736 dose levels on target tissue structure and function in pSS (salivary glands size and echostructure by ultrasound)|Assess effect of two different VAY736 dose levels on target tissue structure and function in pSS (salivary gland function (quantitative) by salivary flow (stimulated and unstimulated)|Assess effect of two different VAY736 dose levels on target tissue structure and function in pSS|To evaluate the effect of two different VAY736 dose levels (s.c. q4w) on pSS disease activity|To evaluate the effect of on self-reported outcomes in pSS patients|To evaluate the change in the physician global assessment of patients's overall disease activity|To evaluate the change in the patients global assessment of their disease activity|To assess the immunogenicity of VAY736 (Anti-VAY736 antibodies)|To assess the immunogenicity of a micodose of rituximab|To assess the pharmacokinetiks of VAY736 in pSS patients	https://ClinicalTrials.gov/show/NCT02495129
140	NCT02464319	A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome	Recruiting	No Results Available	Primary Sjögren's Syndrome	Drug: hrIL-2 active|Drug: hrIL-2 placebo	Peking University People's Hospital|Monash University|Beijing SL Pharmaceutical Company Ltd	Both	Adult	Phase 2	60	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	hrIL-2-SS1	May 30, 2015	June 2015	December 2016	June 4, 2015	June 2015	No Study Results Posted	null	June 2016	Examination of the therapeutic effects (improvement in ESSDAI) of low dose IL-2 in patients with primary Sjögren's Syndrome|Immunological Responses	https://ClinicalTrials.gov/show/NCT02464319
141	NCT02450396	Pregnancy and Medically Assisted Conception in Rare Diseases	Recruiting	No Results Available	Rheumatoid Arthritis|Spondyloarthritis|Psoriatic Arthritis|Systemic Lupus Erythematosus|Antiphospholipid Syndrome|Sjogren Syndrome|Scleroderma|Myositis|Vasculitis|Mastocytosis|Various Autoimmune and/or Systemic and/or Rare Diseases		Assistance Publique - Hôpitaux de Paris|SNFMI |SFR |CRAT 	Female	Child|Adult|Senior		1000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	13.381bis	May 19, 2015	June 2014	December 2019	May 20, 2015	May 2015	No Study Results Posted	EGR2	June 2019	"good" obstetric outcome|Define the best therapeutic management strategies|Conduct pharmacoepidemiologic studies|Analyse the frequency of exposure to various medications (immunosuppressors, biological therapy, corticosteroids) and their maternal and fetal consequences (e.g., infectious complications).	https://ClinicalTrials.gov/show/NCT02450396
142	NCT02422407	Sjögren's Biomarker Study	Recruiting	No Results Available	Healthy|Sjögren's Syndrome		Biogen	Both	Adult|Senior		80	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	999SJ001	March 19, 2015	March 2015	March 2017	October 1, 2015	October 2015	No Study Results Posted	null	March 2017	Gene expression levels in immune cells (innate and adaptive) in salivary gland biopsy samples from participants with and without pSS including healthy volunteers|Gene expression levels in immune cells (innate and adaptive) in blood samples from participants with and without pSS including healthy volunteers|Gene expression levels in epithelial cells in salivary gland biopsy samples from participants with and without pSS including healthy volunteers|Gene expression levels in epithelial cells in blood samples from participants with and without pSS including healthy volunteers	https://ClinicalTrials.gov/show/NCT02422407
143	NCT02402309	A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)	Recruiting	No Results Available	Sjögren-Larsson Syndrome	Drug: Active topical NS2 1% dermatologic cream|Drug: Vehicle placebo 0.0% NS2 dermatologic cream	Aldeyra Therapeutics, Inc.	Both	Child|Adult|Senior	Phase 2	12	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	NS-003	March 17, 2015	March 2015	April 2016	October 1, 2015	October 2015	No Study Results Posted	null	March 2016	Number of Participants with Adverse Events as a measure of Safety and Tolerability|Pharmacokinetics - Peak Plasma Concentration (Cmax)	https://ClinicalTrials.gov/show/NCT02402309
144	NCT02381587	the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Sjogren Syndrome Patients	Not yet recruiting	No Results Available	Primary Sjogren Syndrome With Multisystem Involvement	Other: Retrospective study	Meir Medical Center	Both	Adult|Senior		500	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	HCQ and sjogren	February 16, 2015	April 2015	April 2016	March 2, 2015	March 2015	No Study Results Posted	HAS	April 2016	Arterial cardiovascular events|Cardiac events (myocardial infarction|Thrombosis of peripheral veins|Stroke (stroke and TIA)|Venous thrombosis events|Pulmonary embolism	https://ClinicalTrials.gov/show/NCT02381587
145	NCT02370550	Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome	Not yet recruiting	No Results Available	Sjogren's Syndrome	Drug: Cyclosporin A|Drug: Prednisone|Drug: Placebo|Drug: Calcium carbonate D	Peking University People's Hospital	Both	Adult|Senior	Phase 4	240	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	2014-M03|U1111-1167-1974|ChiCTR-IPR-15005990	February 18, 2015	March 2015	March 2017	February 18, 2015	February 2015	No Study Results Posted	CTRIPS	March 2016	The forced vital capacity (FVC)|The diffusing capacity of carbon monoxide (DLco)	https://ClinicalTrials.gov/show/NCT02370550
146	NCT02370225	Aerobic Exercise in Primary Sjögren's Syndrome	Recruiting	No Results Available	Sjogren's Syndrome	Other: aerobic exercise	Samira Tatiyama Miyamoto|Federal University of São Paulo|Newcastle University|Federal University of Espirito Santo	Female	Adult		45	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)	PRPPG 3363/2012	February 9, 2015	March 2015	March 2016	March 12, 2015	March 2015	No Study Results Posted	AEPSS	December 2015	Change from baseline in fatigue at 16 weeks|Change from baseline in aerobic capacity at 16 weeks|Change from baseline in depression at 8 weeks|Change from baseline in depression at 16 weeks|Change from baseline in disease activity at 16 weeks|Change from baseline in quality of life at 16 weeks|Change from baseline in symptoms at 8 weeks|Change from baseline in symptoms at 16 weeks	https://ClinicalTrials.gov/show/NCT02370225
147	NCT02358213	Evaluation of the Reproducibility Inter-observer of the Ultrasound Anomalies of the Salivary Glands in Sjogren's Disease	Completed	No Results Available	Sjogren's Disease	Procedure: Ultrasound	University Hospital, Brest	Both	Adult|Senior		21	Other	Interventional	Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)	RB 14.133 ETREINTE	January 26, 2015	March 2015	March 2015	March 19, 2015	March 2015	No Study Results Posted	ETREINTE	March 2015	Reproducibility between experts|Reproducibility by the sonographer	https://ClinicalTrials.gov/show/NCT02358213
148	NCT02334306	A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome	Recruiting	No Results Available	Primary Sjögren's Syndrome	Biological: AMG 557/MEDI5872|Other: Placebo	MedImmune LLC|Amgen	Both	Adult|Senior	Phase 2	42	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	D5181C00001	December 12, 2014	June 2015	August 2017	September 24, 2015	September 2015	No Study Results Posted	null	February 2017	Change in the European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) score from Day 1 to Day 99|Outcomes in peripheral blood - Change in plasma cell (PC) levels (including plasma blast [PB] levels) from baseline to Day 99|Outcomes in minor salivary gland tissue - Change in PC levels from baseline to Day 99|Change in focus score from Day 1 to Day 99|Safety and tolerability of multiple subcutaneous (SC) doses of AMG 557/MEDI5872 as measured by safety laboratory tests (hematology, chemistry and urinalysis)|Change in European League Against Rheumatism Sjogren's Syndrome Patient Reported Index (ESSPRI) score from Day 1 to Day 99|Outcomes in peripheral blood - Change in follicular helper T cells (TFH) levels from Day 1 to Day 99|Outcomes in minor salivary gland tissue - Change in TFH levels from Day 1 to Day 99|Safety and tolerability of multiple subcutaneous (SC) doses of AMG 557/MEDI5872 as measured by the number of subjects with adverse events, including serious adverse events, treatment-related adverse events and adverse events of special interest	https://ClinicalTrials.gov/show/NCT02334306
149	NCT02291029	Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome	Recruiting	No Results Available	Primary Sjögren's Syndrome	Drug: CFZ533 active|Drug: CFZ533 placebo	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 2	30	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)	CCFZ533X2203	November 4, 2014	October 2014	February 2017	September 8, 2015	September 2015	No Study Results Posted	null	February 2017	EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)|EULAR Sjögren's Syndrome Patient Reported Intensity (ESSPRI)|Physician global assessment of the patient's overall disease activity (VAS)|Patient's global assessment of their disease activity (VAS)|Short Form (36) Health Survey (SF-36)|Multidimensional Fatigue Inventory (MFI)	https://ClinicalTrials.gov/show/NCT02291029
150	NCT02149420	PD of VAY736 in Patients With Primary Sjögren's Syndrome	Recruiting	No Results Available	Primary Sjögren's Syndrome	Drug: VAY736|Drug: Placebo	Novartis Pharmaceuticals|Novartis	Both	Adult|Senior	Phase 2	30	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	CVAY736X2201|2013-000250-22	September 9, 2013	May 2014	June 2017	May 14, 2015	May 2015	No Study Results Posted	CVAY736X2201	June 2017	Change in EULAR Sjögren's syndrome disease activity index (ESSDAI)|Change in EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)|Change in Short Form (36) Health Survey (SF-36)|Change in Multidimensional Fatigue Inventory (MFI)|Change in the physician's global assessment by means of Visual Analog Scale (VAS)|Change in the patient's global assessment by means of Visual Analog Scale (VAS)|VAY736 serum concentration	https://ClinicalTrials.gov/show/NCT02149420
151	NCT02132585	Cross-sectional Study of Use of Speckle Method in Early Diagnosis of Cardiovascular Dysfunction	Active, not recruiting	No Results Available	Sjogren Syndrome	Procedure: Speckle tracking echocardiography	University of Roma La Sapienza	Both	Adult|Senior		700	Other	Observational	Observational Model: Case Control|Time Perspective: Cross-Sectional	Spk-001	May 5, 2014	January 2010	May 2014	May 5, 2014	February 2014	No Study Results Posted	SPEEDCARS	March 2013	Longitudinal Myocardial Strain reduction in Sjogren Patients|Association between 6minute-walking-test and Longitudinal strain reduction	https://ClinicalTrials.gov/show/NCT02132585
152	NCT02110446	Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome	Recruiting	No Results Available	Sjögren's Syndrome	Drug: SS-1|Drug: Placebo	Chang Gung Memorial Hospital|Chang Gung University|National Science Council, Taiwan|China Medical University, China|China Medical University Hospital	Both	Adult|Senior	Phase 2	60	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	102-2481A	April 1, 2014	February 2014	January 2016	September 22, 2014	February 2014	No Study Results Posted	SS-1	January 2015	Ocular surface disease index (OSDI)|EULAR Sjogren's syndrome patient reported index (ESSPRI)|SJS symptoms Questionnaire|Schirmer's test|Salivary scintigraphy|Oxidative stress and antioxidant capacity|Quality of life (SF-36)|Regulatory effect on cytokine	https://ClinicalTrials.gov/show/NCT02110446
153	NCT02067910	Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome	Recruiting	No Results Available	Sjögren's Syndrome	Drug: Abatacept SC	University Medical Center Groningen|Bristol-Myers Squibb	Both	Adult|Senior	Phase 3	88	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	IM101-473	February 14, 2014	August 2014	July 2018	August 21, 2014	August 2014	No Study Results Posted	ASAPIII	February 2018	ESSDAI|Safety parameters|ESSDAI (at time-points other than 24 weeks)|DAS28(CRP) and DAS28(ESR)|Corticosteroid dose (decrease, stable, increase)|Salivary gland function|Tear gland function|ESSPRI|Patient and Physician Global assessment of disease activity (patGDA, phyGDA)|Multidimensional Fatigue Index (MFI)|Health related quality of life (Short Form-36; SF-36)|Patient Acceptable Symptom State (PASS)|Female Sexual Function Index (FSFI)|NRS score vaginal dryness|Histological change in parotid gland|Laboratory immune markers|EQ-5D|Work Participation and Activity Impairment questionnaire (WPAI)	https://ClinicalTrials.gov/show/NCT02067910
154	NCT02027298	Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study	Withdrawn	No Results Available	Primary Sjogren's Syndrome|Secondary Sjogren's Syndrome|Inflammatory Arthritis|Rheumatoid Arthritis	Drug: Abatacept	Qingping Yao|Bristol-Myers Squibb|The Cleveland Clinic	Both	Adult|Senior	Phase 2	0	Other|Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CC-Yao-2012001	November 18, 2013	November 2013	April 2015	February 2, 2015	February 2015	No Study Results Posted	null	April 2015	Efficacy of Abatacept in patients with inflammatory arthritis and Sjogren's Syndrome|Increase or change in autoantibody profile|Explore the potential efficacy of Abatacept in the exocrine glandular function	https://ClinicalTrials.gov/show/NCT02027298
155	NCT01989819	Primary Sjögren Syndrome	Recruiting	No Results Available	Primary Sjögren's Syndrome	Other: skin biopsy	University Hospital, Limoges	Both	Adult|Senior		55	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	I10 023	November 6, 2013	September 2012	June 2016	December 2, 2013	October 2011	No Study Results Posted	NeuroSenSS	September 2015	To evaluate the cutaneous lymphocytic infiltration|Cutaneous infiltration T, B and Th17	https://ClinicalTrials.gov/show/NCT01989819
156	NCT01971957	Sjogren-Larsson Syndrome: Natural History, Clinical Variation and Evaluation of Biochemical Markers	Recruiting	No Results Available	Sjogren-Larsson Syndrome (SLS)		University of Nebraska	Both	Child|Adult|Senior		50	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	560-12	April 30, 2013	April 2013	July 2017	October 29, 2013	October 2013	No Study Results Posted	SLS	July 2017	Characterize the extent and progression of neurocutaneous disease in patients with Sjogren-Larsson syndrome, and identify useful biomarkers.	https://ClinicalTrials.gov/show/NCT01971957
157	NCT01782235	Efficacy of Tocilizumab in Primary Sjögren's Syndrome.	Recruiting	No Results Available	Primary Sjögren's Syndrome (pSS)	Drug: Tocilizumab|Drug: Placebo	University Hospital, Strasbourg, France	Both	Adult|Senior	Phase 2|Phase 3	110	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	5206|2012-002045-37	January 30, 2013	July 2013	March 2017	March 11, 2014	March 2014	No Study Results Posted	ETAP	January 2017	Improvement of the ESSDAI score equal to or greater than 3 points compared to enrollment.	https://ClinicalTrials.gov/show/NCT01782235
158	NCT02379169	Effects of Sea Buckthorn Oil and Lutein on Eye Health	Not yet recruiting	No Results Available	Risk Factors for Age Related Macular Degeneration	Dietary Supplement: Sea buckthorn oil & lutein|Dietary Supplement: Placebo	Turku University Hospital|Aromtech Ltd.	Both	Adult|Senior		90	Other|Industry	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	SBEYE	November 7, 2014	February 2015	August 2018	February 26, 2015	November 2014	No Study Results Posted	SBEYE	February 2017	Change in macular pigment optical density from baseline to 6 mo|Change in symptoms of dry eye from baseline to 6 mo|Change in serum lipids (Triglycerides, HDL-cholesterol, LDL-cholesterol, total cholesterol) from baseline to 6 mo|Change in serum markers of inflammation (hs-CRP) from baseline to 6 mo|Change in circulating aminotransferases (ALAT, ASAT) from baseline to 6 mo|Change in contrast sensitivity from baseline to 6 mo|Change in vision aquity from baseline to 6 mo|Change in vision functioning from baseline to 6 mo|Change in tear film osmolarity from baseline to 6 mo	https://ClinicalTrials.gov/show/NCT02379169
159	NCT01838252	Hyaluronic Acid Gels for Lower Lid Retraction	Withdrawn	No Results Available	Ectropion	Procedure: Hyaluronic acid|Procedure: Saline	University of California, Los Angeles	Both	Adult	Phase 4	0	Other	Interventional	Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)	12-001629	April 18, 2013	February 2013	May 2014	December 2, 2014	December 2014	No Study Results Posted	null	February 2014	Lower eyelid position|Subjective dry eye symptoms|Objective dry eye signs	https://ClinicalTrials.gov/show/NCT01838252
160	NCT01840683	HELP Therapy for Dry AMD	Active, not recruiting	No Results Available	Non-exudative (Dry) Age-related Macular Degeneration (AMD)	Device: H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)	B.Braun Avitum AG	Both	Adult|Senior		22	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	BA-I-H-1202	April 5, 2013	May 2013	January 2016	November 11, 2014	November 2014	No Study Results Posted	HELPuc	September 2015	To evaluate the effects of H.E.L.P. therapy on the best corrected visual acuity (BCVA) in patients with non-exudative (dry) AMD.|To evaluate the effects of H.E.L.P. therapy on the change in drusen area as assessed by colour photography.|To evaluate the effects of H.E.L.P. therapy in area of abnormal autofluorescence as assessed by Fundus Autofluorescence (FAF).|To evaluate the effects of H.E.L.P. therapy on overall visual functioning as assessed by the Visual Functioning Questionnaire (VFQ)-25 test.|To evaluate the safety of H.E.L.P. therapy by assessing laboratory tests and vital signs.|To evaluate the effects of H.E.L.P. on the integrity of the outer retinal bands as assessed by Optical Coherence Tomography (OCT)|To evaluate the effects of H.E.L.P. therapy on the best corrected visual acuity (BCVA).|To evaluate the effects of H.E.L.P. therapy on the AREDS severity scale as assessed by colour photography.|To evaluate the effects of H.E.L.P. therapy on the incidence and change in area of geographic hypo autofluorescence as assessed by fundus autofluorescence images.|To evaluate the effects of H.E.L.P. on the drusen volume as assessed by Optical Coherence Tomography (OCT)|To evaluate the safety of H.E.L.P. therapy by assessing adverse events (AEs).|To evaluate the safety of H.E.L.P. therapy by physical examination.	https://ClinicalTrials.gov/show/NCT01840683
161	NCT02293538	FID# 114657 in Contact Lens Wearers	Completed	No Results Available	Refractive Error|Symptoms of Ocular Dryness	Drug: FID# 114657 eye drops (10 ml)|Drug: Saline eye drops (15 ml)|Device: Habitual contact lenses	Alcon Research	Both	Adult|Senior		234	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)	LCO242-P001	November 14, 2014	November 2014	July 2015	July 28, 2015	July 2015	No Study Results Posted	null	July 2015	Mean Pre-lens Tear Lipid Layer Thickness (LLT) after 2 hours of lens wear on Day 1|Mean comfortable lens wear time (Time Uncomfortable - Time Insertion) at Baseline and Day 14|Percentage of subjects that experience at least a unit increase from baseline score to Day 14 for overall comfort with lenses (1-10 scale)|Mean change from baseline in comfortable lens wear time (Time Uncomfortable - Time Insertion) to Day 14|Mean Pre-lens Tear Lipid Layer Thickness after 2 hours of lens wear on Day 14	https://ClinicalTrials.gov/show/NCT02293538
162	NCT02024269	Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration	Withdrawn	No Results Available	Dry Macular Degeneration	Biological: Adipose Derived Stem Cells	Bioheart, Inc.	Both	Adult|Senior		0	Industry	Interventional	Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	ADI-US-AMD-001	December 17, 2013	December 2013	June 2017	September 15, 2015	September 2015	No Study Results Posted	null	December 2016	frequency and nature of adverse events|Visual Field analysis (10-2)|Visual Acuity Measurements|Intraocular pressure	https://ClinicalTrials.gov/show/NCT02024269
163	NCT01922128	Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration	Completed	No Results Available	Nonexudative Age-related Macular Degeneration	Drug: MC-1101, Placebo	MacuCLEAR, Inc.	Both	Adult|Senior	Phase 1	20	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	MC-1101-002	August 7, 2013	September 2013	December 2013	April 17, 2014	April 2014	No Study Results Posted	null	November 2013	No significant ocular or systemic adverse events in any of the 20 study subjects	https://ClinicalTrials.gov/show/NCT01922128
164	NCT01920867	Stem Cell Ophthalmology Treatment Study	Recruiting	No Results Available	Retinal Disease|Macular Degeneration|Hereditary Retinal Dystrophy|Optic Nerve Disease|Glaucoma	Procedure: RB (Retrobulbar)|Procedure: ST (Subtenon)|Procedure: IV (Intravenous)|Procedure: IVIT (Intravitreal)|Procedure: IO (Intraocular)	Retina Associates of South Florida|MD Stem Cells	Both	Adult|Senior		300	Other	Interventional	Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label	ICMS-2013-0019.	August 8, 2013	August 2013	August 2017	October 16, 2015	October 2015	No Study Results Posted	SCOTS	August 2016	Visual acuity|Visual fields	https://ClinicalTrials.gov/show/NCT01920867
165	NCT02286089	Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration	Recruiting	No Results Available	Age-related Macular Degeneration	Biological: OpRegen	Cell Cure Neurosciences Ltd.	Both	Adult|Senior	Phase 1|Phase 2	15	Industry	Interventional	Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CCN_CT02	November 2, 2014	April 2015	August 2017	April 13, 2015	April 2015	No Study Results Posted	null	August 2016	Safety and tolerability of OpRegen|Duration of graft survival|Efficacy of the graft	https://ClinicalTrials.gov/show/NCT02286089
166	NCT01890187	Repeatability and Reproducibility of Cirrus HD-OCT Measurements of Illumination Areas Under the Retinal Pigment Epithelium	Completed	No Results Available	Advanced Dry AMD With Geographic Atrophy		Carl Zeiss Meditec, Inc.|DataMed Devices Inc.	Both	Adult|Senior		85	Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	HD-OCT-GA-2010-2	June 24, 2013	November 2010	February 2011	June 27, 2013	June 2013	No Study Results Posted	null	February 2011	Coefficient of variation for area of increased illumination under the RPE (mm^2)|Coefficient of variation of the closest distance to fovea	https://ClinicalTrials.gov/show/NCT01890187
167	NCT02227498	Argus II Retinal Prosthesis System Dry AMD Feasibility Study Protocol	Recruiting	No Results Available	Age Related Macular Degeneration	Device: Argus II Retinal Prosthesis System	Second Sight Medical Products	Both	Adult|Senior	Phase 1	5	Industry	Interventional	Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	CP-04-01	August 25, 2014	October 2014	March 2018	January 16, 2015	January 2015	No Study Results Posted	null	March 2016	The number of adverse events in implanted subjects.|Visual function	https://ClinicalTrials.gov/show/NCT02227498
168	NCT01822873	Study on Visual Function Impairments in Dry Age-related Macular Degeneration	Recruiting	No Results Available	Age Related Macular Degeneration		Duke University|Hoffmann-La Roche	Both	Adult|Senior		210	Other|Industry	Observational	Time Perspective: Prospective	Pro00036248	March 28, 2013	March 2013	null	August 3, 2015	August 2015	No Study Results Posted	null	December 2017	Change in low luminance visual acuity|Change in cone specific contrast sensitivity|Change in contrast sensitivity|Change in macular sensitivity on microperimetry	https://ClinicalTrials.gov/show/NCT01822873
169	NCT02540148	Transpalpebral Micro Current Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration	Not yet recruiting	No Results Available	Age-related Macular Degeneration	Device: Nova Oculus™ Micro-current electrical stimulation|Device: Nova Oculus™ Micro-current electrical stimulation - Sham treatment	The Eye Machine Canada Inc.	Both	Adult|Senior		30	Industry	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	NO001C	September 1, 2015	null	null	September 2, 2015	September 2015	No Study Results Posted	null	September 2016	The primary outcome will be the mean change in visual acuity at the six week visit of the study group versus the control group.	https://ClinicalTrials.gov/show/NCT02540148
170	NCT02130531	Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration	Active, not recruiting	No Results Available	Geographic Atrophy|Age-Related Macular Degeneration	Drug: Emixustat HCl Tablet|Other: Placebo Tablet	Acucela Inc.	Both	Adult|Senior	Phase 1	26	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)	4429-101	May 1, 2014	April 2014	December 2015	July 16, 2015	July 2015	No Study Results Posted	null	September 2015	Area Under the Concentration-Time Curve from time zero to 24 hours [(AUC(0-24h)]|Degree of suppression of the ERG b-wave response post-photobleaching.	https://ClinicalTrials.gov/show/NCT02130531
171	NCT01802866	Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride	Active, not recruiting	No Results Available	Geographic Atrophy	Drug: ACU-4429|Drug: Placebo	Acucela Inc.|Otsuka Pharmaceutical Co., Ltd.	Both	Adult|Senior	Phase 2|Phase 3	480	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	4429-202	February 28, 2013	February 2013	July 2016	July 16, 2015	July 2015	No Study Results Posted	SEATTLE	July 2016	Change from baseline in the total area of the GA lesion(s)|Change from baseline in BCVA score|Frequency of AEs, discontinuations due to AEs, or dose modifications; severity and seriousness of AEs	https://ClinicalTrials.gov/show/NCT01802866
172	NCT02463344	Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD	Enrolling by invitation	No Results Available	Age-Related Macular Degeneration	Biological: MA09-hRPE	Ocata Therapeutics	Both	Adult|Senior		13	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	ACT MA09-hRPE AMD -001 LTFU	May 13, 2015	July 2012	December 2030	June 2, 2015	June 2015	No Study Results Posted	null	December 2029	Number of patients experiencing a grade 2 or greater adverse event related to the cell product or showed any evidence that the cells were contaminated with an infectious agent or showed any evidence that the cells have tumorigenic potential|Exploratory evaluations for potential efficacy endpoints.|Exploratory evaluation for successful engraftment.	https://ClinicalTrials.gov/show/NCT02463344
173	NCT02563782	Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD	Recruiting	No Results Available	Age-Related Macular Degeneration	Biological: Sub-retinal transplantation of MA09-hRPE cells|Drug: tacrolimus and mycophenolate mofetil|Drug: Placebo tacrolimus and mycophenolate mofetil|Procedure: Sham Surgery	Ocata Therapeutics	Both	Adult|Senior	Phase 2	60	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)	MA09-hRPE AMD 02 PORTRAY	September 21, 2015	August 2015	May 2019	September 29, 2015	September 2015	No Study Results Posted	PORTRAY	March 2017	Number of subjects with evidence of graft failure or rejection.|Change in area of geographic atrophy by Optical coherence tomography|Change in area of geographic atrophy by Autofluorescence|Change in average Best Corrected Visual Acuity (BCVA)	https://ClinicalTrials.gov/show/NCT02563782
174	NCT02016508	Safety Study of Use of Autologous Bone Marrow Derived Stem Cell in Treatment of Age Related Macular Degeneration	Recruiting	No Results Available	Age Related Macular Degeneration	Drug: autologous bone marrow derived stem cells	Al-Azhar University|Hassan , Hosny , M.D. M.Sc|Samour , Hany  M.D. M.Sc|Ismail , Mahmoud  M.D. M.Sc|Higazy , Hasan  M.D. M.Sc|Abou el kheir, Wael, M.D. M.Sc.|Gabr, Hala , M.D. M.Sc.|Bakry, Sayed , phD. M.Sc.	Both	Adult|Senior	Phase 1|Phase 2	1	Other	Interventional	Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label	NCT 4619792013|4619792013	May 18, 2013	March 2013	June 2015	December 20, 2013	December 2013	No Study Results Posted	null	April 2015	number of subjects with adverse events|Assessment of visual function changes from the base line	https://ClinicalTrials.gov/show/NCT02016508
175	NCT01799564	Micropulse Laser for Geographic Atrophy	Recruiting	No Results Available	Geographic Atrophy|Age-related Macular Degeneration	Procedure: Micropulse	Institut de la Macula y la Retina	Both	Adult|Senior	Phase 1	15	Other	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Caregiver, Outcomes Assessor)	MPL4DRY	February 25, 2013	August 2012	June 2017	March 23, 2015	March 2015	No Study Results Posted	MPL4DRY	December 2016	Change in area of atrophy as measured with fundus autofluorescence	https://ClinicalTrials.gov/show/NCT01799564
176	NCT02464956	Production of iPSC Derived RPE Cells for Transplantation in AMD	Not yet recruiting	No Results Available	Age Related Macular Degeneration (AMD)		Moorfields Eye Hospital NHS Foundation Trust|Medical Research Council	Both	Adult|Senior		10	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	DACL1011	May 14, 2015	July 2015	April 2016	June 3, 2015	May 2015	No Study Results Posted	null	April 2016	Successful production of a Retinal Epithelial (RPE) layer that fulfils Regulatory Regulation for transplantation. This will be confirmed with standard laboratory characterisation of RPE and completed toxicity and safety studies on the cell layer.	https://ClinicalTrials.gov/show/NCT02464956
177	NCT01782989	Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)	Recruiting	No Results Available	Geographic Atrophy	Drug: ORACEA®|Drug: Placebo	Paul Yates, MD, PhD|MEDARVA Foundation|University of Virginia	Both	Adult|Senior	Phase 2|Phase 3	286	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	16586	January 31, 2013	February 2013	December 2017	June 19, 2015	June 2015	No Study Results Posted	TOGA	July 2017	Rate of enlargement in area of geographic atrophy in the study eye during the treatment period.|Change in Best Corrected Visual Acuity (BCVA)	https://ClinicalTrials.gov/show/NCT01782989
178	NCT02127463	Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration	Recruiting	No Results Available	Non-Exudative Age Related Macular Degeneration	Drug: MC-1101|Drug: MC-1101 Vehicle	MacuCLEAR, Inc.	Both	Adult|Senior	Phase 2|Phase 3	60	Industry	Interventional	Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)	MC-1101-003	April 25, 2014	April 2014	April 2016	April 29, 2014	April 2014	No Study Results Posted	McCP2/3	April 2016	Visual Function|Safety and tolerability (incidence and severity of adverse events, ocular irritability, ocular hyperemia)	https://ClinicalTrials.gov/show/NCT02127463
